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 Temporal lobe epilepsy (TLE) is characterized by hyperexcitability of limbic 
structures. The entorhinal cortex (EC) is involved in the initiation and maintenance of 
TLE. Layers II and III of the EC in particular are hyperexcitable and are more susceptible 
to epileptogenesis. TLE is influenced in a complex manner by the stress-released 
epileptogenic neuropeptide, corticotropin-releasing factor or hormone (CRF/CRH). 
Nevertheless, the action site and underlying mechanisms of CRF in epilepsy are not fully 
understood. Here we found that the EC expresses high levels of CRF and CRFR2R receptors 
without the expression of CRFR1R receptors. CRF increased the frequency of picrotoxin 
(PTX)-induced epileptiform activity via CRFR2R receptors and requires cyclic AMP 
(cAMP). However, application of selective protein kinase A (PKA) inhibitors reduced, 
not completely blocked CRF-induced enhancement of epileptiform activity suggesting 
that PKA is only partially required. Furthermore, endogenously released CRF is also 
involved in the epileptogenesis. 
 Among various ionic conductances maintaining neuronal excitability, the 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and the conducting 
current IRhR has strongly been implicated in TLE. Whereas, layer III of the EC shows 
preferential neuronal loss in TLE, layer II is spared and becomes hyperexcitable. Since 
the stellate neurons of layer II express high levels of HCN channels, we investigated the 
role of HCN channels in CRF- mediated facilitation of epileptiform activity. In the 
 
xvi 
presence of HCN-channel blocker-ZD7288, CRF failed to increase the frequency of 
epileptiform activity but still augmented the numbers of synchronizing events within an 
epileptiform activity and the duration of epileptiform activity. This suggests that part of 
the effects of CRF on epilepsy is mediated via HCN channels. Furthermore, using 
perforated patch clamp recordings we found that CRF increased IRhR recorded from layer II 
stellate neurons via activation of CRFR2R receptors. cAMP, not PKA was responsible for 
CRF-mediated facilitation of IRhR. At the cellular level, CRF depolarized the membrane 
potential resulting in increase in neuronal excitability and action potential firing. These 
mechanisms facilitate an increase in epileptiform activity mediated by CRF, in the EC. 







 Epilepsy is defined as “a disorder of the brain characterized by an enduring 
predisposition to generate epileptic seizures and by the neurobiologic, cognitive, 
psychological, and social consequences of this condition” (International League Against 
Epilepsy (ILAE) (Fisher et al., 2005b). Seizures are complex manifestation of transient, 
abnormal and synchronous enhancement of neuronal excitability in response to adverse 
internal and external variables with different and distinct 0Teffects 0T(Fisher et al., 2005a, 
Engel et al., 2006). Epilepsy is a chronic neurological disorder characterized by two or 
more unprovoked seizures (Duncan et al., 2006). Epileptogenesis is the sequence of 
events in which a normal brain transforms into a hyperexcitable epileptic neuronal 
circuit. Epilepsy is the third most common, multifarious and devastating neurological 
disorder affecting 50 million people worldwide (Hauser and Kurland, 1975, Hirtz et al., 
2007, Kobau et al., 2008) and more than two million people. Epilepsy usually presents in 
childhood and people over 65 years age, but may occur for the first time at any age 
(Hauser et al., 1993, Olafsson et al., 2005). Five percent of the population suffer a single 
seizure at some time in their life.
 
2 
Etiology of Epilepsy 
 Etiology is an important determinant of treatment, prognosis, and clinical course.  
Based on the etiology, the ILAE Commission divided epilepsies into three distinct 
categories (Berg et al., 2010). a. Genetic epilepsies in which seizures are the core 
symptom of a disorder due to a known or presumed genetic defect(s) (Berg et al., 2010). 
b. Structural or metabolic epilepsies which are the result of structural or metabolic 
condition, including acquired disorders and genetic conditions, in which there is a 
separate condition between the genetic defect and the epilepsy (Berg et al., 2010).  
c. Epilepsy of an unknown etiology, also referred to as idiopathic epilepsy, accounts for 
70% of epilepsies where the cause is not currently known, but may be of genetic origin or 
the result of a separate, unrecognized disorder (Hauser et al., 1991, Duncan et al., 2006, 
Berg et al., 2010). 
Seizure Classification 
 Based on the seizure semiology and electroencephalography (EEG), ILAE 
(Gastaut, 1969, Epilepsy, 1981, 1989, Luders et al., 1993, Engel, 2001) classified 
epileptic seizures into: 1. Partial or focal seizures, in which the abnormal electrical 
discharge originates from a localised epileptic focus. Partial seizures can be further 
subdivided into: a. simple partial seizures are the most common type of epilepsy and do 
not affect consciousness. b. Complex partial seizures affect consciousness. In adults, 
partial seizures are most the most common form accounting for 60 – 70 % of all seizures 
(Hauser et al., 1993, Forsgren et al., 1996, Oun et al., 2003).2. Generalized seizures 
involve many parts of the brain. Generalized seizures can be further subdivided into: 
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a. Absence seizures (petit mal) which typically occur in childhood. These seizures are 
distinguishable by brief lapses of consciousness lasting less than 30 seconds such as 
staring, blinking, rolling of the eyes, or arm movements, followed by full awareness. 
b. Myoclonic seizures which are rapid, shock-like jerks of a muscle or group of muscles. 
c. Clonic seizures which occur when several myoclonic seizures occur in succession. 
d. Tonic seizures which cause muscle stiffening, usually in back, legs and arms. e. Tonic-
clonic seizures (grand mal) which are characterized by a stiffening of body (tonic phase) 
and jerking movements (clonic phase). A person sometimes loses consciousness during a 
tonic-clonic seizure and may also have shallow breathing and a loss of bowel/bladder 
control. They are the most common form of generalized seizures. f. Atonic seizures 
which cause an abrupt loss of normal muscle tone for seconds resulting in head nods, jaw 
drops or even falls. Partial seizures may spread to other parts of the brain and transform 
to generalized seizures. 3. Unknown seizures such as epileptic spasms and the events that 
are not clearly diagnosed into one of the categories above. Generalized and partial 
seizures occasionally may lead to continuous or recurrent seizures lasting longer than 30 
minutes without full recovery of consciousness. Continuous generalized seizures, known 
as status epilepticus is a life-threatening condition and requires an immediate 
pharmacological treatment. Continuous partial seizure activity, epilepsia partialis 
continua, though less life threatening, if left untreated for prolonged conditions results in 




Figure 1. ILAE classification of seizures. (Adopted from: Epilepsy.org.au) 
Epileptic and Non-Epileptic Events 
 Electroencephalography (EEG) recordings in epileptic patients show sharp wave, 
spike, spike-and-slow wave complex and the multiple spike-and-slow-wave complex 
patterns which are referred to as epileptiform activity. Subclinical or interictal discharges 
are often observed between seizures which also exhibit the patterns of epileptiform 
activity. However, it must be noted that not all seizures are epileptic. For example, 
medical conditions such as narcolepsy, heat stroke, cardiac arrhythmia and low blood 
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sugar have symptoms similar to epileptic seizures, but show no abnormal electrical 
activity (Hauser et al., 1996). Non-epileptic events can occur in both epileptic and non-
epileptic patients. 
Treatment Strategies 
 Current treatment strategies for seizures focus exclusively on prophylaxis or 
seizure suppression, thus providing only a symptomatic treatment (Rogawski and 
Loscher, 2004) without clear influence on the cause of disease and produce various side 
effects (Pitkanen and Sutula, 2002). Anti-epileptic drugs (AEDs) are the most commonly 
used treatment strategy for epilepsy. AEDs are designed to restore the normal balance 
between excitation and inhibition of the neuronal network (Avoli, 1983, Mody et al., 
1992). AEDs target a number of mechanisms such as: increase the inhibitory 
neurotransmission via gamma-aminobutyric acid (GABA), decrease the excitatory 
glutamatergic transmission, and reduce neuronal excitability by modulation of sodium or 
calcium channels (Figure 2). However, a substantial proportion of patients (~30%) do not 
respond to AEDs (Perucca et al., 2007) and continue to have seizures despite carefully 
optimized drug treatment (Regesta and Tanganelli, 1999).  In patients with intractable 
epilepsy, other treatments may be needed. In some cases, a ketogenic diet rich in fatty 
acids and free from carbohydrates or a vagus nerve stimulator has been proven to be 
helpful. However, the effects have not always been promising (Danielsson et al., 2008). 
Removal of epileptic tissue can be a cure for a select population with clear epileptogenic 
focus. In some cases of febrile seizures, corticosteroid treatment is often preferred. 
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However, there is no easy cure or prophylactic regimen. Intractability to currently  
available anticonvulsants may indicate multiple mechanisms of seizure generation.Hence, 
even when one mechanism is targeted, the others still can exacerbate the disease.  
 
 
Adopted from (Bialer and White, 2010, Loscher and Schmidt, 2012) 
Figure 2.  Clinically approved AEDs with a wide spectrum of mechanisms of action. 
Effects on both inhibitory (left-hand side) and excitatory (right-hand side) 
nerve terminals.  
(AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; 
GABA, γ-aminobutyric acid; GAT-1, sodium- and chloride-dependent 
GABA transporter 1; SV2A, synaptic vesicle glycoprotein 2A). 
 
Therefore, advances in the knowledge of the underlying mechanisms of epilepsies would 
allow for more rational therapeutic approaches to this challenging neurological disorder 
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(Perucca et al., 2007). Temporal lobe epilepsy (TLE) is one of the most prevalent 
intractable epilepsies in adults, and the cellular and molecular basis for the 
pharmacoresistance of the epilepsy has so far remained elusive (Engel, 1996). 
TLE 
 TLE manifests as a partial seizure (Kwan and Brodie, 2000). There are many 
causes of TLE such as brain injuries, brain tumors, vascular malformations and 
developmental abnormalities. TLE can be mesial TLE (MTLE) or lateral TLE. The 
MTLE or limbic epilepsy is the most common form of TLE (Wiebe, 2000) and involves 
the interaction among neuronal networks in limbic structures such as the hippocampus, 
amygdala and the entorhinal cortex (EC) (Engel, 1993). The LTLE is the less common 
form of TLE and arises in the neocortex. In about 60% of TLE patients, seizures spread 
from temporal lobe to the adjacent occipital, frontal, parietal as well as to the temporal 
lobe on the contralateral side of the brain. This process is called secondary generalization. 
The result is a convulsive (grand mal) seizure. Whereas some of the TLE patients 
develop abnormal tissue damage such as the mesial temporal sclerosis, which is 
amenable to resection, the number of options is limited for those without such lesions. 
Therefore, unraveling additional mechanisms would allow new targets for future therapy 
developments not only for patients with non-surgical intractable epilepsy, but also for 
other types of epilepsies. 
TLE and the EC 
 In patients with intractable seizures, seizure onset is frequently detected in the 
hippocampus. However, human and animal studies provide increasing evidence that other 
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structures of the limbic system, such as the amygdala, parts of neocortex, and the EC also 
play important roles. In line with these studies, the EC has been implicated in the 
development and propagation of limbic seizures in TLE patients (Rutecki et al., 1989, 
Spencer and Spencer, 1994, Bartolomei et al., 2001) and in animal models mimicking 
this disorder (Dreier and Heinemann, 1991, Bragdon et al., 1992, Jones et al., 1992, 
Heinemann et al., 1993, Avoli et al., 1996). However, the processes leading to 
spontaneous seizures involving the EC have not been fully determined. 
Structure of the EC 
 Anatomically, the EC is a six-layered pivotal structure (layers I-VI, 10TFigure10T 2) 
(Mulders et al., 1997) integrating information from the parahippocampus, prefrontal 
cortex, and the frontal cortex (Apergis-Schoute et al., 2006).  Hence the EC is considered 
the gateway mediating the majority of connections between the hippocampus and other 
cortical areas (Witter et al., 1989, Witter et al., 2000a, Witter et al., 2000b). Layer I is the 
molecular layer, which has a scarcity of cells, whereas layer IV is the cell-sparse, fiber-
rich narrow layer that constitutes the lamina dissecans. Layer II is mainly made up of 
densely packed, large and medium sized pyramidal and stellate cells. The most abundant 
cell type throughout layer II in medial EC (mEC) is the stellate cells, located within the 
superficial and middle layer II. The soma of these cells is quite variable but their spiny 
dendritic tree is their defining characteristic. Layer III consists of a high density of 
pyramidal neurons (Dickson et al., 1997, Gloveli et al., 1997). Sensory inputs from 
olfactory structures, parasubiculum, perirhinal cortex, claustrum, amygdala and neurons 
in the deep layers of the EC (layers V–VI) converge onto the superficial layers (layer 
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II/III) of the EC (Witter et al., 1989, Burwell, 2000) which give rise to dense projections 
to the hippocampus. The axons of the stellate neurons in layer II of the EC form the 
perforant path that innervates the dentate gyrus and Cornu Ammonis (Steward and 
Scoville, 1976), whereas those of the pyramidal neurons in layer III form the 
temporoammonic pathway that synapses onto the distal dendrites of pyramidal neurons in 
CA1 and the subiculum (Steward and Scoville, 1976, Witter et al., 2000a, Witter et al., 
2000b). Furthermore, neurons in the deep layers of the EC (layers V–VI) relay a large 
portion of hippocampal output projections back to the superficial layers of the EC 
(Kohler, 1986, Dolorfo and Amaral, 1998a, b, van Haeften et al., 2003) and to other 
cortical  areas (Witter et al., 1989). Accordingly, the EC is not only involved in the 
induction and maintenance of TLE (Spencer and Spencer, 1994, Avoli et al., 2002), but 
also closely involved in the consolidation and recall of memories (Haist et al., 2001, 
Squire et al., 2004, Dolcos et al., 2005, Steffenach et al., 2005), Alzheimer's disease 
(Hyman et al., 1984, Kotzbauer et al., 2001), and schizophrenia (Falkai et al., 1988, 
Arnold et al., 1991, Joyal et al., 2002, Prasad et al., 2004). 
Role of the EC in TLE 
 Clinical and animal studies show that the EC is a site of seizure initiation and 
maintenance. The EC is also involved in acutely induced epileptiform discharges 
(Walther et al., 1986, Wilson et al., 1988, Jones and Lambert, 1990, Pare et al., 1992, 
Stringer and Lothman, 1992, Bear and Lothman, 1993, Rafiq et al., 1993). Preferential 
loss of layer III neurons of the EC is seen in both human TLE (Kim et al., 1990, Du et al., 
1993) as well as animal models of epilepsy (Du and Schwarcz, 1992, Du et al., 1995). 
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With the onset of epilepsy, CA3 neurons are lost and the Schaffer collateral (SC) 
pathway connecting CA3 to the CA1 pyramidal neurons is disrupted (Ben-Ari and 
Cossart, 2000). Under these conditions, the TA pathway has been suggested as a major 
 
(Adopted and modified from © 2012 Neural Circuits and Memory Lab). 
 
Figure 3.  EC forms the gateway to the hippocampus and other cortical areas. 
Superficial layers (II, III) send sensory inputs to the hippocampus. 
Stellate neurons in layer II  form Perforant path  with DG cells and CA3 
Pyramidal neurons in layer III form Temporoammonic pathway 
connecting CA1 and subiculum 
CA1 sends it output to layers V/VI of the EC  which in turn relay back to 
the superficial layers.  
 
excitatory drive to the principal neurons of the CA1 region (Barbarosie et al., 2000, Avoli 
et al., 2002, Wu and Leung, 2003). The neurons of layer II are well spared in TLE. 
However, they become hyperexcitable (Bear et al., 1996) due in part to a reduction in 
inhibitory input (Kobayashi and Buckmaster, 2003), and proexcitatory alterations in 
sodium channel gating parameters (Hargus et al., 2011). Additionally, removal of the 
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parahippocampal gyrus along with the EC, showed better seizure management in patients 
with refractory epilepsy (Siegel et al., 1990, Engel, 1993). 
Auras and Seizure Precipitation Factors 
 In some cases, epileptic seizure can be predicted. Auras are symptoms that occur 
in some epileptic patients before the onset of a seizure. These include a strange taste or 
odor or sounds, feeling of numbness or tingling, anxiety and nausea. Whereas in some 
epileptic patients, seizures are triggered (Berg et al., 1995). Triggering factors can be 
environmental or endogenous in origin and cause a transient lowering of the seizure 
threshold, or chemical or physiological stimulation capable of precipitating an ictal event 
(Aird, 1983, Nakken et al., 2005). In most cases, multiple factors are involved in setting 
off seizures and are rarely predictable. However, in some cases it is possible to determine 
what triggers the onset of seizures. In addition to determining the underlying causes of a 
seizure disorder, identifying and managing factors that precipitate seizures can aid in 
developing behavioral or lifestyle changes that can improve seizure control and the 
patient’s need for medication. Some known potential precipitants that often encourage 
seizures include: alcohol consumption, alcohol withdrawal, various medical conditions 
such as multiple sclerosis, fever, photosensitivity, drugs, sleep deprivation, anxiety and 
stress.  
Stress and Epilepsy 
 Stress is the more frequently self-reported precipitant of seizures in patients with 
refractory epilepsy (Frucht et al., 2000, Spector et al., 2000, Nakken et al., 2005, Haut et 
al., 2007, Sperling et al., 2008). Stress can be internal or environmental signals perceived 
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as a potential threat (Behan et al., 1995b, Cortright et al., 1995, Hsu and Hsueh, 2001, 
Calabrese et al., 2007). Although stress does not cause epilepsy, it can make a person 
more prone to seizures. Additionally, getting anxious about having seizures can add to 
stress and thus forms a vicious cycle of seizures and stress. In support of these clinical 
studies, stress pathways have been shown to promote neural activity in a variety of ways, 
suggesting its direct contribution to hyperexcitability resulting in spontaneous seizures. 
The mammalian brain is equipped with numerous sensing devices to identify stress, as 
well as mechanisms to respond to the stress signals (Behan et al., 1995b, McEwen, 2011). 
Mild or acute stress is often adaptive as it enhances functions of the hippocampus and 
other brain regions by augmenting synaptic plasticity, to cope with the situation if it ever 
occurs again (Behan et al., 1995b, Cortright et al., 1995, Joels et al., 2011). However, the 
same mechanisms when chronically activated render the brain more susceptible to 
numerous detrimental effects (Cortright et al., 1995, Joels et al., 2007, Joels et al., 2011), 
including seizure precipitation.  
Stress Mechanisms Activate the Excitatory Neuropeptide CRF 
 How does the brain detect and reacts to a stressful stimulus and trigger seizures? 
When an individual appraises a situation as a threat, stress responses get activated 
(Lazarus and Folkman, 1984). Two major components are principally engaged to adopt to 
stress challenges; i) the sympathetic-adrenomedullary system is activated for rapid- and 
short-lived responses and results in increased systemic levels of norepinephrine and 
epinephrine, and increased levels of norepinephrine in the brain. ii) The hypothalamic-
pituitary-adrenal (HPA) system is activated for delayed, sustained responses and involves 
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various hormones and neuropeptides (Behan et al., 1995b, Cortright et al., 1995, De 
Kloet et al., 1998, Calabrese et al., 2007) (for a detailed review, see (Turnbull and Rivier, 
1997)). Activation of the HPA axis involves the limbic system in the brain, which is 
composed of the amygdala, prefrontal cortex and the hippocampus (Figure 3). The 
amygdala creates an emotional response in reaction to stress, while the hippocampus 
creates a memory of the threat to deal with it in a better way in future. Stressful or 
threatening stimuli pass through the amygdala and reach the paraventricular nucleus 
(PVN) of the hypothalamus via neurochemical pathways. The PVN then releases 
corticotropin releasing factor (CRF) into the adenohypophyseal portal circulation 
(Whitnall, 1993). CRF activates CRF receptors on anterior pituitary corticotrophs 
resulting in the release of adrenocorticotrophin hormone (ACTH) (Turnbull and Rivier, 
1997). ACTH then signals the pituitary gland to stimulate adrenal glands to release 
cortisol (corticosterone in rodents) (Vale et al., 1981) Cortisol and other glucocorticoids 
released from the adrenal cortex, help to mobilize resources for sustained actions. These 
include changes such as increased blood glucose and lipid levels, increased heart rate, 
blood pressure as well as immune responses involving circulating T cells, B cells and 
lymphocytes. In the short term, these resources are useful in helping the body to deal with 
stressors. However, chronic activation of these mechanisms may contribute more to the 
development of various diseases. 
Overview of the CRF System 
 CRF is known as the most potent epileptogenic neuropeptide. Therefore, 
appreciation of the circuitry affected by the CRF-system is particularly germane to 
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understand the effects of CRF on seizure threshold, seizure susceptibility and 
epileptogenesis. CRF plays a fundamental role in responding to stressors exposed to the 
human body (Hemley et al., 2007) and mediates both short and long term responses to 
stress.  
 
Figure 4.  Schematic illustration of the HPA axis signaling. 
Stress signals stimulate CRF neurosecretory cells in PVN of the 
hypothalamus to release CRF.  
CRF then activates ACTH secretion from corticotrophs of anterior 
pituitary gland.  
ACTH travels to adrenal glands of kidneys and stimulates release of 
cortisol.  
To protect against prolonged activity as well as help regain homeostasis, 
the HPA system is carefully modulated through negative feedback exerted 
by cortisol at anterior pituitary, PVN and the hippocampus. 
 - : Inhibition, + : Activation. 
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Dysregulation of the CRF–system has been implicated in a myriad of “stress-related” 
disorders, including epilepsy (Baram and Hatalski, 1998, Hauger et al., 2006). 
 CRF is known to change neuronal function in a rapid and reversible manner. CRF 
is an excitatory neuromodulator (Dunn and Berridge, 1990). There are numerous CRF 
pathways outside the HPA axis (Lymangrover and Brodish, 1973) where CRF acts as 
central neuromodulator (Swanson et al., 1983). The CRF signaling system comprises of 4 
CRF family ligands, a binding protein, and two receptors (Vale et al., 1981, Behan et al., 
1995a, Steckler and Holsboer, 1999, Ryabinin et al., 2002, Fekete and Zorrilla, 2007). 
 CRF family ligands. CRF, urocortins (UcnR1R, UcnR2 Ror stresscopin-related peptide, 
and UcnR3R or stresscopin), urotensins (UTnR1R, UTnR2, RandR RUTnR3R), and sauvagine (Svg) are 
the four ligands that belong to the CRF family. 
 CRF gene location and homology. CRF is found in all vertebrates (Batten et al., 
1990, Bhargava and Rao, 1993) and mammals (Paull et al., 1982, Sakanaka et al., 1986, 
Stolp et al., 1987) including primates (Millan et al., 1986) and humans (Chan et al., 1982, 
Binder and Nemeroff, 2009). The CRF gene contains two exons separated by an intron 
that is around ~600–800 base-pair long (Furutani et al., 1983, Shibahara et al., 1983, 
Jingami et al., 1985, Roche et al., 1988, Morley et al., 1991, Stenzel-Poore et al., 1992b, 
Keegan et al., 1994, Mimmack et al., 1998) and is located on chromosome 8q13. The first 
exon contains mostly untranslated mRNA, while the second exon encodes the entire 
translated region of CRF precursor. Although CRF mRNAs differ in length in all these 
species, the CRF gene is highly conserved and the same gene sequence is found in almost 
all animals (De Souza et al. 2000). Human CRF is identical to that of rat and differs from 
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ovine by only seven amino acids. This homology of the CRF gene has been exploited to 
learn more about human CRF as well as to develop antagonists, using CRF from other 
species (Hemley et al., 2007). 
 CRF structure. CRF is a 41 amino acid polypeptide (Vale et al., 1981), cleaved 
from the pro-peptide at dibasic amino acids (lysine or arginine residues) (Shibahara et al., 
1983, Roche et al., 1988, Morley et al., 1991, Stenzel-Poore et al., 1992b). The glycine 
residue in the C-terminal, Gly-Lys serves as a template for amidation. The 3D- structure 
of the peptide is not fully discovered. However, it is believed that CRF is made up of a 
defined alpha helix with an unstructured terminal end at each side, which may also form a 
helix when bound to a receptor. This double helical confirmation might possibly be the 
biologically active form of CRF (Grigoriadis et al. 2001). CRF is released at synaptic 
terminals upon depolarization (Smith et al. 1986) and is characterized by saturable, 
reversible, specific binding to its receptors (De souza et al, 1985). 
 CRF Distribution. CRF is ubiquitous in the mammalian central nervous system 
(CNS) (Swanson et al., 1983, Dautzenberg and Hauger, 2002). Apart from the PVN and 
lateral area of the hypothalamus, CRF immunoreactivity has been detected in various 
extra-hypothalamic regions such as cerebellar cortex (Cha and Foote, 1988, Arzt and 
Holsboer, 2006), locus coeruleus (Cha and Foote, 1988), olfactory bulb (Bassett et al., 
1992) and limbic structures including the EC (Bassett et al., 1992, Park et al., 2003), 
amygdala (Bassett and Foote, 1992) and the hippocampus (Yan et al., 1998, Park et al., 
2003). The distribution of CRF neurons in the brain is consistent with its role in 
endocrine, physiological and behavioral responses to stress. The identity of the CRF-
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containing neurons can be either GABAergic (Primus et al., 1997, Yan et al., 1998) or 
glutamatergic (Cain et al., 1991, Valentino et al., 2001). 
 Regulation of CRF Expression. Stress adaptation involves either down-or up- 
regulation of CRF expression, depending on the brain regions. CRF gene transcription 
site involves the promoter and 5′-upstream region containing glucocorticoid response 
 
Adopted from: Holmes, A. et al., Trends Pharmacol Sci 24 (11), 580 (2003)   
 
Figure 5.  Distribution of CRF mRNA. 
CRF-like immunoreactivity is seen in regions including the hypothalamus, 
amygdala, BNST and cortex.0T  
 
element (GRE) and cyclic AMP (cAMP) response elements (CRE), and Pit-1,   Oct-1, 
Oct-2 and Caenorhabditis elegans Unc86(POU) transcription factor binding sites (Roche 
et al., 1988, Xu et al., 2001, Parham et al., 2004). In rodents, exogenous central CRF 
administration generates a large increase in CRF mRNA expression in the PVN (Parkes 
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et al., 1993). This finding is consistent with studies in which acute or chronic stress 
significantly increases endogenous CRF mRNA expression in hypothalamic PVN and the 
central nucleus of amygdala (Ma et al., 1999, Makino et al., 1999, Figueiredo et al., 2003, 
Shepard et al., 2005). Additionally, increases in CRF mRNA induced by acute stress are 
mediated via CRE-binding protein (CREB) phosphorylation by protein kinase A (PKA) 
(Itoi et al., 1996, Kovacs and Sawchenko, 1996). While acute stress initially triggers a 
rapid increase in CRF mRNA in rat PVN, chronic stress results in an increase in 
inducible cAMP early repressor (ICER) mRNA expression, thus preventing cAMP-
dependent CRF gene transcription (Shepard et al., 2005). Failure of this regulatory 
mechanism could therefore be one of the major contributors for CRF hypersecretion. 
 Regulation of CRF release. In addition to the gene transcription mediated 
control, CRF release is regulated by a number of other factors such as angiotensin, 
vasopressin, neuropeptide-Y, substance P, atrial natriuretic peptide, activin, melanin 
concentrating hormone, β-endorphin, and possibly CRF itself. Whereas neurotransmitters 
such as acetylcholine, norepinephrine, histamine and serotonin promote CRF release, 
GABA inhibits the release of CRF. In addition, cytokines such as interleukin-1β, tumor 
necrosis factor, eicosanoids, and platelet-activating factor have been shown to activate 
the HPA-axis by increasing hypothalamic CRF expression.  
 CRF Receptors. CRF transduces neuronal and endocrine signals by binding to 
two G-protein coupled receptor types, CRF receptor 1 (CRFR1R; also known asR RCRFR1and 
CRHR1) and CRF receptor 2 (CRFR2R; also known as CRFR2 and CRHR2) (Perrin et al., 
1993, Lovenberg et al., 1995b, Dautzenberg and Hauger, 2002). CRF receptors are 
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component of seven transmembrane α-helical proteins that belong to class II or B 
receptor superfamily.. Human CRFR1 Rand CRFR2 Rreceptor genes are mapped to 
chromosomes 17q21 and 7p14, respectively (Polymeropoulos et al., 1995, Meyer et al., 
1997). CRF-mediated signal transduction is triggered when CRF-type ligand binds to the 
interior of the helical protein core (Perrin and Vale, 1999, Hillhouse and 
Grammatopoulos, 2006) (De Souza, 1995, Dautzenberg and Hauger, 2002, Chatzaki et 
al., 2006, Fekete and Zorrilla, 2007). Distinct genes encode for CRFR1 Rand CRFR2 Rreceptors, 
while retaining a 70% peptide sequence homology in all species. Post translational 
splicing results in isoforms with variants having altered intercellular or transmembrane 
domains (Lovenberg et al., 1995a, Zmijewski and Slominski, 2010). CRF receptors are 
highly conserved and are present in a wide variety of vertebrates, including but not 
limited to mouse (Vita et al., 1993, Kishimoto et al., 1995, Perrin et al., 1995a, Stenzel et 
al., 1995), rat (Chang et al., 1993, Perrin et al., 1993, Lovenberg et al., 1995a) and 
humans (Chen et al., 1993, Vita et al., 1993). CRFR1R and CRFR2R display distinct 
pharmacological profiles (De Souza, 1995, Dautzenberg and Hauger, 2002, Chatzaki et 
al., 2006, Fekete and Zorrilla, 2007) and are widely distributed in the extrahypothalamic 
circuits; with some splice variants located in specific peripheral tissues (Potter et al., 
1994, Chalmers et al., 1995, Hiroi et al., 2001). Recently, a third CRF receptor subtype 
termed CRFR3R was cloned from catfish, which is highly homologous to CRFR1R receptor. 
However, no such subtype has been reported to date in humans (Arai et al., 2001). 
 CRFR1R receptors. CRFR1R was cloned from several species, including human, 
mouse, rat (Chen et al., 1993, Dieterich et al., 1997) and has no known functional genetic 
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polymorphism. CRFR1R is the primary endocrine transduction pathway of CRF, and is 
found at high densities in the anterior pituitary. In the brain, CRFR1 Rare expressed mainly 
in the medial septum, pituitary, cerebral cortex, cerebellum, hippocampus, amygdala, 
raphe nuclei, hindbrain, and olfactory bulb (De Souza et al., 1985, Chang et al., 1993, 
Primus et al., 1997, Rominger et al., 1998, Hauger et al., 2006). Peripheral CRFR1R 
receptors are located in adrenal gland, ovaries, testes and skin. The mRNA distribution 
for CRFR1 Rcorrelates well with the known distribution of CRF binding sites (Bittencourt 
and Sawchenko, 2000b). When expressed in cells, CRFR1 Rexhibits an identical in vitro 
pharmacological profile similar to that in brain and pituitary. Based on these 
observations, several novel CRF receptor-antagonist molecules were developed to probe 
the physiological significance of this receptor (McCarthy et al., 1999). CRF binds with 
high affinity to CRFR1 R(Perrin and Vale, 1999, Hauger et al., 2003). Urocortins (Ucn), 
urotensins, and sauvagine also bind to CRF receptors. Among the urocortins, Ucn1 binds 
to CRFR1 Rreceptors with affinity similar to CRF. Both CRF and Ucn1 can therefore be 
considered as endogenous ligands for CRFR1 R(Hauger et al., 2003). 
 CRFR2R receptors. CRFR2R receptors are known to exist in 4 isoforms: CRFR2Rα, 
CRFRR2Rα-tr, CRFR2Rβ, and CRFR2Rδ. CRFR2Rα is a 411 amino acid protein and is about 71% 
identical to CRFR1R (Lovenberg et al., 1995b). CRFR2Rα is localized to subcortical regions, 
including lateral septum, paraventricular, ventromedial nuclei of the hypothalamus and 
the EC (Lovenberg et al., 1995a). CRFR2Rα-tr is a novel short variant of 2α-isoform cloned 
from the rat amygdala (Miyata et al., 1999). CRFR2Rα-tr exhibits differential brain 
expression and is pharmacologically related to CRFR2Rα. CRFR2Rβ is a 431 amino acid 
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protein and differs from CRFR2Rα in that the first 34 amino acids in the N-terminal 
extracellular domain are replaced by 54 different amino acids (Perrin et al., 1995b). 
CRFR2Rβ is localized primarily to heart, skeletal muscle, cerebral arterioles and choroid 
plexus (Chalmers et al., 1995). CRFR2Rδ in human brain (Kostich et al., 1998) is expressed 
in amygdala and the hippocampus, whereas no such subtype exists in rat. The binding 
affinity of CRF to CRFR2R is 15 times lower than that of CRFR1R (Perrin and Vale, 1999, 
Hauger et al., 2003). CRF-like peptides UTn1, sauvagine, generally binds to CRFR2R. More 
importantly, Ucn2 and Ucn3 have nearly 100 times greater affinity to CRFR2R than CRF 
(Hauger et al., 2003), and show little or no effect on CRFR1R. Thus Ucn is hypothesized as 
the endogenous ligand for CRFR2R (Vaughan et al., 1995). 
 CRF-binding protein. CRF levels are maintained by a soluble 322 amino acid, 
37 kDa glycoprotein, known as CRF-binding protein (CRF-BP). CRF-BP buffers the 
amount of free CRF in extracellular compartment (Jahn et al., 2005), both in periphery 
and in the brain. CRF-BP was first inferred from studies in pregnant humans and was 
thought to block the effects of CRF, to attenuate activation of the HPA axis. Later, 
studies established that CRF-BP is highly expressed in brain, plasma, heart, lungs, 
intestines, and placenta (Potter et al., 1992, Boorse and Denver, 2006, Vitoratos et al., 
2006). In rats, CRF-BP expression is restricted to the brain. Immunohistochemistry and 
in situ hybridization studies reveal that CRF-BP is expressed in various areas of rat brain 
including cerebral cortex, amygdala, hippocampus, and sensory relay nuclei associated 
with auditory, olfactory, vestibular, and trigeminal systems (Potter et al., 1992). Thus, the 
differential distribution of brain CRF-BP and CRF receptors presents multiple distinct 
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sites of interaction with CRF (Behan et al., 1993a). CRF-BP is possibly involved in the 
brain maintenance of the synaptic CRF concentrations either by presynaptic uptake or by 
modulating the quantity of neuropeptide that activates CRF receptors at the membrane 
interface (Turnbull and Rivier, 1997). 
 In the periphery, CRF-BP binds to CRF and dimerizes to prevent CRF-binding 
receptor bioavailability (Behan et al., 1995a). In the brain, CRF-BP is membrane-
associated (Behan et al., 1995). The interaction between CRF and CRF-BP is possibly 
due to maintenance of synaptic CRF concentrations either by presynaptic uptake or 
modulation of neuropeptide availability that activates CRF receptors (Turnbull and 
Rivier, 1997). The role of CRF-BP is not completely understood. However, the 
differential distribution of CRF-BP shows that the protein has much broader potential for 
buffering, inhibiting, or enhancing the effects of CRF family of peptides binding to its 
receptors. Furthermore, the type of effect depends on localization and concentration 
(Seasholtz et al., 2002), similar to the receptors. CRF-BP binds CRF and urocortins 
(except UcnR3R) with affinity similar to or greater than CRF receptors, and inhibits CRF-
induced ACTH releasing properties of CRF receptor agonist in vitro in a dose-dependent 
fashion (Lowry et al., 1996).  
 CRF-mediated second messenger signaling. Both CRFR1R and CRFR2R are primarily 
coupled to GRsR proteins resulting in activation of adenylyl cyclase (AC) and increase in 
levels of cAMP, which activates PKA (Dautzenberg and Hauger, 2002, Grammatopoulos 





Adopted from (Kuperman and Chen, 2008) 
 Figure 6.  Schematic representation of the mammalian CRF–urocortin family of 
peptides, receptors and binding proteins.(Kuperman and Chen, 2008).  
Colored arrows indicate the receptors and binding proteins with which 
each ligand interacts.  
Dotted arrow indicates relatively lower affinity, as compared with 
unbroken arrow.  
CRF has relatively lower affinity for CRFR2R compared with its affinity for 
CRFR1R. Ucn1 has approximately equal affinity for both receptors; Ucn2 and 
Ucn 3 are selective for CRFR2R.  
The signaling cascade also includes CRF-BP and the recently identified 
sCRFR2aR. Both CRF-BP and sCRFR2aR bind to CRF and urocortin 1 with high 
affinity.  
 
coupling competence and potency to interact with other G-protein systems including GRqR, 
GRiR, GRoR, GRi1/2R, and GRzR (Grammatopoulos et al., 2001). Thus CRF can modulate various 
signaling cascades and kinases comprising of protein kinase B (PKB), protein kinase C 
(PKC), mitogen-activated protein (MAP) kinases and intracellular Ca P
2+
P concentrations in 




Grammatopoulos and Chrousos, 2002, Hauger et al., 2006). The biological actions of 
CRF are likely to be mediated by these CRF receptors and their intracellular signals.  
 CRF/receptor complex internalization and sensitivity. Following CRF receptor 
binding, G-proteins are phosphorylated and the α-subunits are dissociate from βγ to 
stimulate second messenger cascades. CRF receptors are then rapidly desensitized by G-
protein related kinases (GRKs) via phosphorylation of serines and threonines in  
C-terminus (Dautzenberg et al., 2002, Kohout and Lefkowitz, 2003, Krasel et al., 2005, 
Moore et al., 2007, Kelly et al., 2008) and the receptor signaling is then terminated. CRFR1R 
and CRFR2R form complexes with β-arrestins, which are bound to clathrin and β-adaptin 
and form vesicles and are internalized. (Oakley et al., 2007, Markovic et al., 2008). These 
desensitized receptors are then dephosphorylated, resensitized by specific phosphatases 
and are recycled to the plasma membrane. 
 Functions of CRF and CRFRs. Hypothalamic CRF coordinates 
neuroendocrine, autonomic and behavioral responses to stress  (Behan et al., 1993b, 
Behan et al., 1995b, Behan et al., 1996, Burrows et al., 1998a, Bale et al., 2000, Chan et 
al., 2000, Bale et al., 2002, Chatzaki et al., 2002, Bale and Vale, 2004, Boorse et al., 
2006). The complexity of the stress-related mechanisms endows CRF with both positive 
as well as detrimental effects. CRF promotes survival under acute or short stressful 
conditions, lasting seconds to minutes, by potentiating synaptic plasticity (Behan et al., 
1995b, Cortright et al., 1995, Chen et al., 1996a, Henry et al., 2005, Florio et al., 2007b, 
Holsboer and Ising, 2008), yet its excess and/ or dysregulation can contribute to a number 
of detrimental effects (Linton et al., 1990, Behan et al., 1995b, Behan et al., 1996, 
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Karolyi et al., 1999, Hsu and Hsueh, 2001, Lewis et al., 2001). These results are further 
corroborated by overexpression of CRF in forebrain which led to learning and memory 
defects (Linton et al., 1993).  
 
 
Adopted from (Dautzenberg and Hauger, 2002) 
Figure 7.  CRFR signaling pathways and their regulation. 
CRFR1R and CRFR2R receptors signal mainly through cAMP/PKA signaling.  
CRFRs also signal via the PLC/PKA pathway.  
GRK3mediated CRFR desensitization, internalization and recycling 
(might differ based on the specific cellular and/or neuronal background). 
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Hippocampal synaptic potentiation involves CRF-CRFR1R signaling. Mice lacking CRFR1R 
showed attenuated synaptic plasticity (Lovejoy et al., 1998), and have memory deficits 
(Contarino et al., 1999). 
The extra hypothalamic effects of CRF within the CNS are predominantly 
excitatory in various brain regions such as locus ceruleus (Valentino et al., 1983), 
hippocampus (Siggins et al., 1985) cerebral cortex, hypothalamus and in lumbar spinal 
cord motor neurons (Dunn and Berridge, 1990, Owens and Nemeroff, 1991). CRF 
modifies sensory stimulus (Valentino et al., 1983), induces behavioral excitation, 
stimulating activities such as rearing and grooming (Siggins et al., 1985, Britton et al., 
1986).CRF has inhibitory actions in the lateral septum, thalamus, and hypothalamic PVN 
(Dunn and Berridge, 1990, Owens and Nemeroff, 1991). CRF increases GABA release 
via CRFR1R in rat amygdala and hypothalamic slices (Bagosi et al., 2008, Bagosi et al., 
2012). CRF increases vigilance and decreases slow-wave sleep at doses below those 
affecting locomotor activity or pituitary-adrenal function  and higher doses can be 
epileptogenic (Ehlers et al., 1983). CRF-mediates increase of presynaptic glutamate 
release (Lovenberg et al., 1995a), as well as enhanced postsynaptic excitability which is 
potentially related to CRF-induced suppression of after-hyperpolarization (Aldenhoff et 
al., 1983). CRF released by IL-1 (Berkenbosch et al., 1987, Sapolsky et al., 1987, 
Busbridge et al., 1989) mediates fever, thermogenesis, and ACTH release (Naitoh et al., 
1988, Busbridge et al., 1989). CRF in the leukocytes may also induce ACTH and 
endorphin release (Blalock, 1989) which are responsible for natural killer activity (Irwin 
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et al., 1988) and inflammatory responses. CRF family is also a novel angiogenic regulator 
in endogenous and inflammatory conditions (Im et al., 2010). 
To help determine the role of CRFRs mediating various biologic actions of CRF, 
a number of selective peptide agonists and antagonists were discovered and developed, 
based on the receptor differential ligand affinities. For example, Ucn III, has a higher 
affinity to CRFR2R than CRFR1R and is commonly used as a selective CRFR2 Ragonist (Hsu and 
Hsueh, 2001, Lewis et al., 2001). Similarly, ovine CRF is often used as a CRFR1R specific 
agonist as its affinity to CRFR1R is two orders greater than CRFR2R (Ruhmann et al., 1998a). 
Through mutation and artificial structural constraints, receptor-specific peptide agonists 
and antagonists were developed (Ruhmann et al., 1998a, Rivier et al., 2002b, Tezval et 
al., 2004, Rivier et al., 2007). For example antalarmin (ANT), and anti-sauvagine-30 
specifically binds CRFR1R and CRFR2R respectively (Chen et al., 1996b, Schulz et al., 1996, 
Webster et al., 1996, Holsboer and Ising, 2008). 
Stress responses in general, are mediated by the activation of CRFR1R receptors 
(Owens and Nemeroff, 1991, Chen et al., 1996b, Webster et al., 1996, Chen et al., 1997, 
Smith et al., 1998), whereas CRFR2R receptors might be involved in the initiation of 
secondary-stress responses to regain homeostasis (see review (Bale and Vale, 2004, 
Gysling, 2004). These differential roles may in part be attributed to the activation of the 
distinct central sources of CRF (Bagosi et al., 2008, Bagosi et al., 2012).Central 
administration of CRF have anorexic effects (Vaughan et al., 1995, Spina et al., 1996, 
Smagin et al., 1998) and peripheral administration has been shown to slow gastric 
emptying and decrease food intake (Asakawa et al., 1999, Nozu et al., 1999).These 
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effects are mediated by CRFR2R receptors. Activation of CRFR1R receptors in the brain can 
suppress feeding independently of CRFR2R receptor-mediated mechanisms and independent 
time-courses (Hotta et al., 1999, Reyes et al., 2001, Inoue et al., 2003). Stress stimulates 
colonic motility via CRFR1R receptor activation and does not involve CRFR2R receptors 
(Tache et al., 2001, Martinez et al., 2002, Tache et al., 2002). CRFR2R receptors are 
predominantly involved in stress related feeding behavior (Keck et al., 2005), energy 
balance (Bakshi et al., 2002), altering glucose metabolism and decreasing insulin 
sensitivity in skeletal muscle, altering pancreatic β-cell (Bale et al., 2003, Chen et al., 
2006, Li et al., 2007) and cardiovascular function  (Hashimoto et al., 2004, Boonprasert 
et al., 2008). CRFRs play differential roles in mediating gastrointestinal regulation 
following stress (Stengel and Tache, 2010). While CRFR2R inhibits gastric emptying and 
small intestine motility to slow digestion, CRFR1R increases colonic motility. In some stress 
related responses such as stress-induced relapse of drug seeking and stress-mediated 
inhibition of reproduction, both the CRFRs may contribute to an observed response 
(Sarnyai et al., 2001, Li et al., 2006, Kalantaridou et al., 2007, Wise and Morales, 2010). 
The role of CRF and CRFRs is further elucidated by various genetically 
engineered mouse models. a. CRF deletion mutant –CRF-knock-out (CRF KO): CRF KO 
mice are phenotypically normal and display behavioral responses similar to the control 
mice (Muglia et al., 1995, Dunn and Swiergiel, 1999, Weninger et al., 1999), have low 
levels of basal plasma concentrations of CORT. (Muglia et al., 1995). In both the WT and 
KO, stress-induced behaviors were attenuated by CRFR1R antagonists. CRF KO mice 
generated from heterozygotes show adrenal insufficiency and those from the homozygous 
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mating died within 24 hours due to improper lung function caused by glucocorticoid 
deficiency. b. CRF overexpressing (CRF-OE) mice: Constitutive CRF-OE resulted in 
elevated plasma CORT, ACTH, altered HPA axis and Cushingnoid phenotypes (Stenzel-
Poore et al., 1992a, Dirks et al., 2002, Lu et al., 2008); reduced locomotor activity and 
increased anxiety and stress (Stenzel-Poore et al., 1992a, Dedic et al., 2012), reduced 
sensitivity to the anxiolytic effects of CRFR1R antagonists, GABAA and glutamate receptor 
agonists in response to stress-induced hyperthermia (Vinkers et al., 2012).  
To explore the functional significance of CRFR binding sites, single and double 
mutant mice were generated by knocking out CRFRs (Bale et al., 2002) Koob 2001. a. 
CRFR1R mutant mice: CRFR1R null mutants are normal and fertile when born from 
heterozygotes. However, progeny from homozygous female died within two days after 
birth due to lung dysplasia. The CRFR1R mutant mice have low plasma concentration of 
CORT and showed reduced anxiogenic-like responses compared to the control littermates 
(Smith et al., 1998, Contarino et al., 1999). Diminished neuronal activity and reduced 
anxiety-like behaviors were also observed in conditional CRFR1R KOs, including the 
neuronal circuitries of the anterior forebrain and limbic system, indicating that these 
behaviors are independent of the HPA axis (Muller et al., 2003, Nguyen et al., 2006). b. 
CRFR2R mutant mice: These mice exhibit normal fertility with no gross abnormality. These 
mice show increased anxiety-like behavior, hypertension, increased blood vessel density 
and are hypersensitive to the HPA axis mediated stress responses (Bale et al., 2000). 
CRFR2R KO mice show attenuation of stress-coping behaviors and a reduced duration of 
Ucn-1 induced anorexia. c. Double mutant mice: Mice with the CRFR1R and CRFR2R 
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receptors knocked out show decreased basal CORT and ACTH, increased PVN, CRF and 
AVP. These double mutants also show an altered reactivity of the HPA axis (Preil et al., 
2001, Bale et al., 2002), as well as gender differences in exploratory emotionality and 
non-genomic transmission of stress-coping traits from mothers to male offspring (Bale et 
al., 2002). These results corroborate the pharmacological evidence in rats thus supporting 
a role of endogenous CRF family peptides and receptors in regulation of homeostasis.  
 Functional roles of CRF-BP. Multiple functional roles have been suggested for 
CRF-BP, which are controlled by the specific cellular or physiological context (Seasholtz 
et al., 2002, Westphal and Seasholtz, 2006). CRF-BP can have an inhibitory role on the 
activity of CRF or Ucn1 by sequestration from the receptors, or by mediating clearance 
or degradation of the complex. This has been supported by the studies which show that 
CRF-BP binds to placental CRF and prevents the inappropriate activation of CRF R1R 
expressing pituitary corticotropes, during pregnancy (Linton et al., 1990, Florio et al., 
2007a). Furthermore, CRF binding might trigger the clearance of CRF: CRF-BP complex 
when levels of CRF increase during late pregnancy or through CRF injection and thus 
decrease the plasma CRF levels (Linton et al., 1990, Woods et al., 1994). The inhibitory 
role of CRF-BP is supported by in vitro cell culture assays in which pre-incubation of the 
CRF with mouse or human CRF-BP showed a reduced CRFR1R-mediated ACTH release 
(Potter et al., 1991, Cortright et al., 1995) and cAMP (Boorse et al., 2006). The inhibitory 
role of CRF-BP is further confirmed by CRF-BP mutant mouse models (for review see 
(Seasholtz et al., 2002). CRF-BP-overexpression in the anterior pituitary show unaltered 
concentrations of ACTH, but increased CRF and arginine-vasopressin levels, suggesting 
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a compensatory role of the hormones (Burrows et al., 1998b). When CRF-BP transgene 
was overexpressed in the brain, pituitary, kidney, heart, kidney, spleen, lung, adrenals, 
and liver, CRF-BP accumulated in plasma similar to that of humans (Lovejoy et al., 
1998). An increased inhibition of CRF or UCN activity was suggested in these animals 
due to impaired stress response to lipopolysaccharide injection and increased weight gain 
(Spina et al., 1996). In CRF-BP deficient mouse, CORT and ACTH were normal. 
However, these mice showed a decreased food intake and weight gain, increased anxiety-
like behavior in elevated plus maze and defense withdrawal tests were exhibited by male 
animals (Karolyi et al., 1999). 
In contrast, studies support that CRF-BP could enhance or prolong ligand activity 
by increasing its half-life and delivering it to the receptors. CRF potentiates N-methyl-D-
asparate (NMDA) receptor-mediated synaptic transmission and induced cocaine-seeking 
behavior in VTA, via CRFR2R, and these effects were blocked by CRF-BP-specific 
antagonist, CRF6-33 (Ungless et al., 2003, Wise and Morales, 2010). While CRF-BP 
exhibit an enhancing effect involving CRFR2R signaling, and all the studies demonstrating 
an inhibitory role for CRF-BP involved CRFR1,R these differential effects of CRF-BP on 
CRF at these two receptors requires further investigation. In addition to the above roles, 
CRF-BP could also mediate ligand or receptor-independent activity via interactions with 
other unknown receptors or binding proteins (Chan et al., 2000). 
Role and Relevance of CRF in Epilepsy 
 CRF is known to change the neuronal function in a rapid and reversible manner. 
CRF has been implicated in a variety of neurological diseases including affective 
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disorders and epilepsy (Baram and Hatalski, 1998, Hauger et al., 2006). CRF is highly 
expressed in brain regions associated with developmental seizures, such as the 
hippocampus and amygdala (Gray and Bingaman, 1996). For example, 
intracerebroventricular injection of CRF induces seizures (Ehlers et al., 1983, Weiss et 
al., 1986a, Marrosu et al., 1987, Marrosu et al., 1988) and seizures alter the expression of 
CRF (Greenwood et al., 1997, Smith et al., 1997, Takahashi et al., 1997, Piekut and 
Phipps, 1998, Jinde et al., 1999, Wang et al., 2001b), CRF-BP (Smith et al., 1997, Wang 
et al., 2001b, Park et al., 2003) and CRF receptors (Wang et al., 2001b, An et al., 2003, 
Park et al., 2003) supporting the notion that CRF is the most potent epileptogenic peptide 
(Baram and Hatalski, 1998). CRF immunoreactivity has been detected in the cortex (Cha 
and Foote, 1988, Arzt and Holsboer, 2006), locus coeruleus (Cha and Foote, 1988), 
olfactory bulb (Bassett et al., 1992) and the limbic structures including the EC (Bassett et 
al., 1992, Park et al., 2003), hippocampus (Yan et al., 1998, Park et al., 2003) and 
amygdala (Bassett and Foote, 1992). CRF may also contribute to seizure-related neuronal 
loss (Ribak and Baram, 1996). Additionally, picomolar amounts of CRF have been 
shown to induce prolonged limbic seizures involving amygdala and the hippocampus 
(Baram et al., 1992, Baram and Hatalski, 1998). The proconvulsant effects of CRF are 
largely age-specific with infants being more susceptible to seizures than adults (Baram 
and Schultz, 1991a). 
 Despite a tremendous volume of descriptive work that supports the involvement 
of CRF in stress-mediated epileptogenesis; several essential issues regarding the roles of 
CRF in epilepsy have not been addressed. For example, intracerebroventricular  
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Table 1. Terminology and definitions. 
Terminology Definition 
Epilepsy Brain disorder characterized by uncontrolled, excessive, 
synchronous neuronal activity resulting in spontaneous, 
recurrent seizures 
Seizure Clinical condition associated with a transient hyper-synchronous 
neuronal discharge 
Epileptogenesis Complex process, which alters a normal brain circuit into 
hyperexcitable network, leading to spontaneous, recurrent 
seizures. (Clark and Wilson 1999) 
Epileptiform- 
activity 
The spike waves, sharp waves, spike and wave activity, or other 
rhythmic waveforms that may be associated with epilepsy 
Homeostasis The property of a system that regulates its internal environment 
and tends to maintain a stable, relatively constant condition of 
properties such as temperature or pH 
Uictogenesis generation of epileptic seizures 
Seizure-
precipitant 
Any stimuli that can precipitate a seizure in a person with or 
without epilepsy 
Stress Any disruption of homeostatic balance (Robert Sapolsky) 
Stressor A specific threat to the body  
Stress response Attempt of the body to deal with the stressor 
Stress 
hormones 
Mediators which address the specific aspects of a stressor 
Inter-ictal state Interval between seizures or convulsions 
Post-ictal state Altered state of consciousness after a seizure 
Status- 
epilepticus 
A state of continuous seizure activity 
POU proteins Eukaryotic transcription factors containing a bipartite DNA 
binding domain referred to as the POU domain. The acronym 
POU is derived from the names of three transcription factors, 
the pituitary-specific Pit-1, the octamer-binding proteins Oct-1 
and Oct-2, and the neural Unc-86 from Caenorhabditis elegans 
(Clerc et al., 1988, Finney et al., 1988, Ingraham et al., 1988, 




application of CRF can influence almost all brain regions. However, this raises several 
important questions; 1) what is the action site in the brain for the effects of CRF on 
epilepsy? 2) Which type of CRF receptors is involved in CRF-mediated facilitation of 
epilepsy? 3) What are the signaling molecules required for CRF-mediated facilitation of 
epilepsy? Further understanding of these mechanisms will advance our knowledge about 
CRF-mediated integration of the synaptic signals, the firing rates of neurons, and 
consequently, the input to the hippocampus via TA pathway as well as to other cortical 
regions.  
Ion channels modulating epileptiform activity and neuronal excitability 
 Neuronal hyperexcitability plays an important role in epileptogenesis. 0T Neuronal 
excitability is regulated by a number of active membrane properties such as voltage-gated 
or ligand-gated ion channels, passive membrane properties such as resting membrane 
potential, resistance, capacitance etc. An increase in action potential (AP) frequency 
enhances neuropeptide release.  
Hyperpolarization Activated Cyclic Nucleotide  
Channels and the Cation Current, IRh 
 
 Changes in the expression and function of ion channels, particularly the 
hyperpolarization activated cyclic nucleotide (HCN) channels (Chen et al., 2001, Wang et 
al., 2001a, Bender et al., 2003, Powell et al., 2008, Marcelin et al., 2009) are known to be 
mechanistically linked to epilepsy. Therefore better understanding of the mechanisms 
that lead to abnormal activity is important as it provides molecular targets for 






Figure 8.  Schematic representation of AP firing of a neuron. 
1. A stimulus causes the NaP
+
P channels to open. Once the action threshold 
is reached, more NaP
+
P channels open. Influx of NaP
+ 
Pcauses depolarization, 
as the cell membrane becomes more positive.  
2. The NaP
+
P channels close and the KP
+
P channels open. Due to slower 
kinetics of the KP
+ 
Pchannels, the depolarization takes longer to be 




P channels at the 
same time. Thus the membrane becomes neutral preventing another AP. 
3. With the KP
+
P channels open, the membrane begins to repolarize back 
toward its rest potential 
4. The repolarization typically overshoots the rest potential to about            
-90 mV. This is called hyperpolarization which prevents the neuron from 
AP firing, especially in the opposite direction. assureing the signal is 
proceeding in one direction. 




P pump brings the membrane back to 
its resting state of -70 mV. (Adopted from (K. X. Charand;2002)). 
 
 
 HCN channels are cation channels and contain six-transmembrane helices 
(S1-S6). HCN channels generate inward cationic currents designated as IRhR, when the 
membrane potential is hyperpolarized (Hofmann et al., 2005, Wahl-Schott and Biel, 
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2009) and de-activates on depolarization (Robinson and Siegelbaum, 2003).  IRhR produces 




P ions. IRhR is critically involved in the 
maintenance of the neuronal resting membrane potential, passive membrane properties, 
pacemaker activity, rebound burst firing in heart and brain, reduction of dendritic 
summation, as well as governing neuronal network responses (Robinson and Siegelbaum, 
2003); Accilli et al. 2002; Robinson & Siegelbaum, 2003; Santoro & Baram 2003; 
Poolos, 2004; Maccaferri and McBain 1996; Luthi and McCormick 1998; Magee 199; 
Santoro and Baram 2003; Biel et al 2009; Hofmann et al 2005). 
 Its presence in stellate cells was initially established from the observation of a 
sag-like response during injection of negative current steps (Alonso and Llinas, 1989, 
Jones, 1994). Subsequent voltage-clamp experiments have investigated the kinetics, 
voltage dependence, and pharmacology of IRh Rin stellate cells (Richter et al., 1997, 
Dickson et al., 2000, Richter et al., 2000, Nolan et al., 2007, Giocomo and Hasselmo, 
2008). 
 HCN channels are regulated at several levels by intracellular signaling cascades 
including but not limited to cAMP, PIPR2R, TRIP8b, as well as voltage-gated potassium 
channels. HCN channels assemble in tetramers HCN1, HCN2, HCN3, HCN4 (Hofmann 
et al. 2005) which are expressed heterologously. They are non-selective cation channels 
that are distributed differentially throughout the brain (Luthi and McCormick 1998) and 
exhibit developmental expression patters unique to the HCN isoforms with distinct IRhR. 
For example, kinetics of HCN1>HCN2 or HCN4, whereas in terms of sensitivity to 
cAMP HCN1< HCN2 or HCN4. The S4 segment of the channel is positively charged and 
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serves as a voltage sensor, while the C terminus contains a cyclic nucleotide binding 
domain that confers regulation by the cyclic nucleotides cGMP and cAMP, which 
stimulates by direct interaction with the HCN channel protein and not by protein 
phosphorylation (Hofmann et al. 2005). HCN channels are blocked by ZD7288 (Richter 
et al., 1997, Dickson et al., 2000, Nolan et al., 2007) and Cs P
+  
P(Alonso and Llinas, 1989, 
Klink and Alonso, 1993, Dickson et al., 2000, Richter et al., 2000). IRh Rin stellate cells, but 
not mEC pyramidal cells, can be activated by the cAMP analog 8-Bromo-c-AMP 
(Richter et al., 2000). Consistent with these electrophysiological data, gene expression 
data from the Allen Brain Atlas indicates that mRNA levels of HCN1 and HCN2 are 
particularly high in layer II of the mEC. Antibody labeling also suggests strong HCN1 
expression in superficial layers of the mEC (Notomi and Shigemoto, 2004, Nolan et al., 
2007), whilst HCN2 and HCN3 show moderate expression (Notomi and Shigemoto, 
2004). However, antibody labeling could reflect HCN1 channels expressed in the 
dendrites of pyramidal cells with somata in layers III and V (Shah et al., 2004, 
Rosenkranz and Johnston, 2006). Studies demonstrate that a reduced IRhR and changes in 
HCN channel expression are observed in epileptic patients and animal models of 
epilepsy. HCN subunits can co-associate and form heterologous systems (Much et al., 
2003). In the hippocampal tissue, heteromerization is markedly enhanced by seizures 
resulting in altered properties of IRhR, significantly enhancing network excitability (Chen et 
al 2001a; Simeone et al. 2005). IRhR depolarizes the resting membrane potential (Biel et al 
2009; Hofmann et al 2005; Robinson & Sielgelbaum 2003) and hence a decline in IRhR 
might be expected to reduce excitability. However, a decrease in IRhR was accompanied 
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after enhanced neuronal excitability during kainate-induced MTLE in the EC layer III 
(Shah et al. 2004) and in the hippocampus of pilocarpine-epileptic animals (Jung et al., 
2007, Marcelin et al., 2009). This inhibition of IRhR has been suggested to enhance 
pyramidal cell dendrite excitability by increasing the availability of Ca P
2+
P channels (Tsay 
et al. 2007), as well as by amplifying the membrane resistance (Magee 1998; Stuart and 
Sprutson 1998).  
 
Adopted from: Eduardo E. Benarroch, Neurology 2013;80;304-310 (Benarroch, 2013) 
 
Figure 9. Structure and functions of hyperpolarization-activated cyclic nucleotide-
gated channels. 
The four subunits of HCN channels form the central pore.  
Each subunit consists of a six-transmembrane core and the cytosolic 
amino (N)-terminal and carboxy (C)-terminal domains.  
The proximal portion of the cytosolic C-terminal domain contains the 
cyclic nucleotide-binding domain (CNBD), which mediates modulation by 
cyclic nucleotides, such as cAMP.  









IRhR blockers, such as ZD7288 and CsCl have been shown to decrease electrically induced 
paroxysmal discharges in vivo, suggesting antiepileptic effects for compounds that 
decrease the IRhR (Kitayama et al. 2003). 
CRF and Ih 
 CRF can act on a number of ionic conductances including IK(Ca) (Aldenhoff et 
al., 1983). IKir (Kuryshev et al., 1997) and IRhR (Qiu et al., 2005b). CRF augments IRhR, and 
neuronal firing in the VTA dopamine neurons (Wanat et al., 2008). 
Overall Hypothesis, Approach and Outcomes 
 Abundant evidence suggests that CRF is a potent epileptogenic neuropeptide and 
has been reported to facilitate epilepsy in various other regions of the brain, such as the 
hippocampus, amygdala etc. In this regard, CRF mRNA was observed in the EC 
(Lovenberg et al., 1995b), but the role and relevance of CRF and its receptors in the EC is 
not well established. In other brain regions CRF can increase neuronal firing rate through 
activation of the cAMP-PKA pathway (Aldenhoff et al., 1983, Haug and Storm, 2000, 
Jedema and Grace, 2004), and can act on a number of ionic conductances including, but 
not limited to IRhR (Qiu et al 2005). Since the EC is an important structure involved in TLE 
and mRNA of CRF receptors have been detected in the EC by in situ hybridization 
(Lovenberg et al., 1995b), we hypothesized that CRF would directly interact with its 
receptors and facilitates epileptiform activity via modulation of the HCN channels, and IRhR 




 The work presented in this dissertation was conducted to extend the current 
knowledge on the role and relevance of CRF in facilitating epilepsy. The main objective 
of this project was to determine the role of CRF in facilitating epileptiform activity in the 
EC using the well-established picrotoxin (PTX)-slice seizure model of epilepsy. The 
specific aims were: 
 To investigate the role of CRF in facilitating epileptiform activity in the EC. 
 To determine the signaling mechanisms involved in CRF-mediated facilitation of 
epileptiform activity. 
 To determine the role of HCN channels in CRF-mediated facilitation of 
epileptiform activity. 
 To determine the signaling mechanisms involved in CRF-mediated modulation of 
HCN channels and IRhR current. 
 To determine the role of CRF in modulating neuronal excitability. 
 
Figure 10.  Summary of specific aims. 
EC
Role of CRF in PTX-induced epileptiform activity
Signaling mechanisms
Role of HCN channels 
Extracellular field recordings from layer-III of the EC











aCSF : Artificial cerebro-spinal fluid
PTX : Picrotoxin
In vitro
Horizontal brain slices containing the EC
Signaling mechanisms in modulation of Ih






 To test our central hypothesis, we first examined the presence of CRF and its 
receptors in the EC using immunocytochemistry and western blot techniques. We found 
that the EC expresses CRF and CRFR2R receptors. However, no detectable CRFR1R was 
found. Using extracellular field recordings, we examined the effects of CRF on PTX-
induced epileptiform activity recorded from the entorhinal slices. The PTX-induced 
seizure model resembles the simple partial and generalized forms of human epilepsy 
(Fisher, 1989, Sierra-Paredes and Sierra-Marcuno, 1996, Sarkisian, 2001). PTX is a 
GABARAR receptor antagonist and blocks the chloride channels thus acting as a convulsant. 
 
 
Apoted from : 2015 Quizlet LLC. 
Figure 11. Schematic representation of the GABAA receptor complex. 
Five subunits form a transmembrane chloride-gated pore. 
The receptor complex has binding sites for GABA, Benzodiapene, 
Barbiturates and Picrotoxin.  
 
 Furthermore, clinical studies (Du et al., 1993) as well as experimental models of 
TLE supported the preferential loss of layer III pyramidal neurons in the mEC (Schwob 
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et al., 1980, Clifford et al., 1987, Du et al., 1995, Ribak et al., 1998, Jutila et al., 2001, 
Bartolomei et al., 2005). Hence, we studied the role of CRF in facilitating the PTX-
induced epileptiform activity in layer III of the mEC. Our results demonstrate that CRF 
facilitated the induction of epileptiform activity in the presence of subthreshold 
concentration of PTX which normally would not elicit epileptiform activity. Bath 
application of the inhibitor for CRF-BPs, CRF6-33, also increased the frequency of PTX-
induced epileptiform activity suggesting that endogenously released CRF is involved in 
epileptogenesis. CRF-induced facilitation of epileptiform activity was mediated via CRFR2R 
receptors because pharmacological antagonism and knockout of CRFR2 Rreceptors blocked 
the facilitatory effects of CRF on epileptiform activity. Application of the AC inhibitors 
blocked CRF-mediated facilitation of epileptiform activity and elevation of intracellular 
cAMP level by application of the AC activators or phosphodiesterase inhibitor increased 
the frequency of PTX-induced epileptiform activity. These data demonstrate that CRF-
induced increases in epileptiform activity are mediated by an increase in intracellular 
cAMP. However, application of selective PKA inhibitors reduced, but not completely 
block  CRF-induced enhancement of epileptiform activity suggesting that PKA is only 
partially required.  
 Since layer II is spared and becomes hyperexcitable in various experimental 
models of epilepsy and HCN channels are highly expressed in layer II stellate neurons, 
we examined the role of HCN channels in CRF-mediated facilitation of epileptiform 
activity. Application of ZD 7288, a blocker of the HCN channels, significantly reduced 
the frequency of epileptiform activity but increased the numbers of the synchronizing 
events within single epileptiform activity and the duration of individual epileptiform- 
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activity. In the presence of ZD 7288, CRF failed to increase the frequency of epileptiform 
activity but still augmented the numbers of synchronizing events and duration in an 
epileptiform activity suggesting that part of the effects of CRF on epilepsy is mediated 
via HCN channels. CRF increased IRhR currents recorded from layer II stellate neurons via 
activation of CRFR2R receptors. cAMP, not PKA was responsible for CRF-mediated 
facilitation of IRhR. Our results provided a cellular mechanism to explain the effects of CRF 
in epilepsy. Furthermore, at the cellular level, CRF depolarized the membrane potential 
and increased action potential firing rate of the stellate neurons thus resulting in 




MATERIALS AND METHODS 
Slice Preparation 
 Horizontal brain slices (350 µm) including the EC, subiculum and hippocampus 
were cut using a vibrating blade microtome (VT1000S; Leica, Wetzlar, Germany) from 
Sprague-Dawley rats (13- to 18-day-old), wild-type (WT) and CRFR2R knockout (KO) mice 
(1 month) as described previously (Xiao et al., 2009b, Deng et al., 2010b, Wang et al., 
2011, Wang et al., 2012). After being deeply anesthetized with isoflurane, animals were 
decapitated and their brains were dissected out in ice-cold saline solution that contained 
(in mM) 130 NaCl, 24 NaHCOR3R, 3.5 KCl, 1.25 NaHR2RPOR4R, 0.5 CaClR2R, 5.0 MgClR2R, and 10 
glucose, saturated with 95% OR2R and 5% COR2R (pH 7.4). Slices were initially incubated in 
the above solution at 35°C for 40 min for recovery and then kept at room temperature 
(~24°C) until use. 
Recordings of Epileptiform Activity from the Entorhinal Slices 
 Slices were bathed in the extracellular solution comprised (in mM) 130 NaCl, 24 
NaHCOR3R, 5 KCl, 1.25 NaHR2RPOR4R, 2.5 CaClR2R, 1.5 MgClR2R and 10 glucose, saturated with 
95% OR2R and 5% COR2R (pH 7.4). Spontaneous epileptiform activity was induced by 
including the GABARAR receptor blocker PTX (100 µM) in the preceding extracellular 
solution (Deng et al., 2006, Wang et al., 2013). An electrode containing the extracellular 
solution was placed in layer III of the EC to record epileptiform activity. After stable 
spontaneous epileptiform activity occurred, which 
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usually took ~20 min, CRF was applied in the bath. The epileptiform events were initially 
recorded by Clampex 9.2 and subsequently analyzed by Mini Analysis 6.0.1. 
 
Figure 12.  Extracellular field recordings from layer III of the EC. 
Recordings were made from layer III of the EC. aCSF produced no 
epileptiform activity.  
Whereas, addition of 100 µM PTX to the aCSF  induced epileptiform 
activity in the brain slices. 
 
Whole-Cell Recordings 
 Whole-cell recording is a well established and most commonly used patch clamp 
technique. Whole-cell configuration offers lower resistance and complete exchange 
between molecules in the pipette solution and the cytoplasm, due to disruption of the 
membrane patch. Whole-cell configuration has two main modes of recording: the 
voltage-clamp mode, in which the voltage is held constant allowing the study of ionic 
currents, and the current-clamp mode, in which the current is controlled enabling the 
study of changes in membrane potential. However, the disadvantage of this technique is 
Extracellular field recordings from layer-III of the EC















electrode dialyzing, which is the replacement of the soluble cell contents by the contents 
of the pipette solution resulting in alteration of cell properties. 
 
 
Adopted from : bem.fi/book, modified from Hamill et al., 1981 (Hamill et al., 1981) 
Figure 13.  Schematic representation of the whole-cell configuration. 
1. The glass pipette is in contact with the cell membrane. 
2. A tight gigaohm seal is formed by gentle suction; 3, more suction 
 causes the membrane to rupture resulting in the whole-cell configuration. 




 In the current project, whole-cell recordings using a Multiclamp 700B amplifier 
(Molecular Devices, Sunnyvale, CA) in current- or voltage-clamp mode were made from 
the stellate neurons in layer II of the medial EC, visually identified with infrared video 
microscopy (Olympus BX51WI) and differential interference contrast optics. The 
recording electrodes were filled with (in mM) 100 potassium (KP
+
P)-gluconate, 0.6 EGTA, 
2 MgClR2R, 8 NaCl, 2 ATPR2RNa, 0.4 GTPNa, 40 HEPES, and 7 di-tris-phosphocreatine (pH 
7.4, 290–300 mOsm/L). The extracellular solution comprised (in mM) 130 NaCl, 24 
NaHCOR3R, 3.5 KCl, 1.25 NaHR2RPOR4R, 2.5 CaClR2R, 1.5 MgClR2R, and 10 glucose, saturated with 
95% OR2 Rand 5% COR2R (pH 7.4).  
 Action potentials (APs) were recorded in the preceding extracellular solution 
supplemented with bicuculline (10 μM) and CGP55845 (1 μM) to block GABARAR and 
GABARBR responses, respectively, and 6,7-dinitroquinoxaline-2,3-dione (DNQX, 10 μM) 
and DL-2-amino-5-phosphonopentanoic acid (DL-APV, 50 μM) to block glutamatergic 
transmission. For most of the cells, a positive current injection was required to bring the 
resting membrane potential (RMP) to ∼−50 mV to induce AP firing. CRF was applied 
after the AP firing had been stable for 5∼10 min. To avoid potential desensitization 
induced by repeated applications of CRF, only one cell was recorded from each slice. 
Data were filtered at 2 kHz, digitized at 10 kHz, acquired online, and analyzed after line 
using pCLAMP 9 software (Molecular Devices). Frequency of APs was calculated by 
Mini Analysis 6.0.1 (Synaptosoft, Decatur, GA). 
 Holding currents (HCs) at −60 mV were recorded from layer II stellate neurons. 
The preceding extracellular solution was supplemented with TTX (0.5 μM) to block AP 
firing. HCs at −60 mV were recorded every 3 s and then averaged per minute. We 
 
48 
subtracted the average of the HCs recorded for the last minute prior to the application of 
CRF from those recorded at different time-points to zero, the basal level of HCs, for 
better comparison.  
Perforated Patch Clamp Recordings 
 Perforated patch clamp method is very similar to the whole-cell configuration. In 
this method the patched membrane is not ruptured by suction after the formation of the 
gigaohm seal. The electrode solution contains small amounts of an antifungal or 
10Tantibiotic 10T agent, such as 10Tamphotericin-B10T, 10Tnystatin 10T, or 10Tgramicidin 10T, which diffuses into the  
 
Adopted from: the National Institute for Physiological Sciences, 2009 
Figure 14.  Illustration of perforated patch clamp recording. 
The electrode solution contains small amounts of antibiotic agent, such as 
amphotericin-B, which diffuses into the membrane patch and forms small 
pores in the membrane.  
Only monovalent ions can pass through the pore and divalent and second 








membrane patch and forms small pores in the membrane thus providing electrical access 
to the cell interior (Linley, 2013). 
 The advantage of the perforated patch clamp technique is that it allows 
equilibration of only small monovalent ions between the patch pipette and the cytosol. 
However, larger divalent ions such as Ca P
2+
P and signaling molecules such as cAMP, 
cannot permeate through the pores. This helps in the maintenance of endogenous levels 
of most intracellular signaling molecules, and reduced current rundown as in cell-
attached recordings (Linley, 2013). On the other hand, the disadvantages of using the 
perforated patch are: it can take a significant amount of time for the antibiotic to perforate 
the membrane; due to the perforation process the patch may rupture resulting in whole-
cell mode and thus the antibiotic contaminates the entire cell contents; perforated patch 
offers a higher access resistance compared to that of the whole-cell recordings as the 
pipette tips are occupied by the cell membrane which may decrease current resolution 
and increase recording noise. 
 In our current experiments, we used perforated-patch recordings to record HCN-
channel currents (IRhR) from layer II stellate neurons in horizontal slices as described 
previously (Deng and Lei, 2007, Deng et al., 2010a). The extracellular solution 
comprised (in mM) 130 NaCl, 24 NaHCOR3R, 3.5 KCl, 1.25 NaHR2RPOR4R, 2.5 CaClR2R, 1.5 
MgClR2R and 10 glucose, saturated with 95% OR2R and 5% COR2R (pH 7.4). Tetrodotoxin (0.5 
µM) was included in the extracellular solution to block action potentials. Recording 
pipettes were tip-filled with the intracellular solution comprising 100 K P
+
P-gluconate, 0.6 
EGTA, 5 MgClR2R, 8 NaCl, 2 ATPR2RNa, 0.3 GTPNa and 40 HEPES (pH 7.3) and then back-
filled with freshly prepared K P
+
P-gluconate intracellular solution containing amphotericin B 
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(200 µg/ml, Calbiochem, San Diego, CA). Patch pipettes had resistance of 6-8 MΩ when 
filled with the preceding solution. A 5-mV hyperpolarizing test pulse was applied every 5 
s to monitor the changes of the series resistance and the process of perforation. Stable 
series resistances (50-70 MΩ) were usually obtained ~30 min after the formation of 
gigaohm seals. For those cells showing abrupt reduction in series resistance during 
membrane perforation suggesting the simultaneous formation of whole-cell 
configuration, experiments were terminated. Perforated-patch configurations were 
verified by examining the series resistance again at the end of the experiments. Data were 
included for analysis only from those cells showing <15% alteration of series resistance. 
Western Blot 
 Brain tissues for western blot experiments were taken from 10 rats (18-day-old). 
For each rat, horizontal brain slices were cut initially and the medial EC region was 
punched out from the slices under a microscope. The isolated brain region was lysed in 
tissue protein extraction buffer containing protease inhibitors (Pierce, Rockford, IL). The 
lysates were centrifuged at 10,000×g for 10 min to remove the insoluble materials and 
protein concentrations in the supernatant were determined (Bradford, 1976). An 
equivalent of 40 µg total protein was loaded to each lane. Proteins were separated by 
12% SDS–PAGE and transferred to the polyvinylidene difluoride (PVDF, Immobilon-P, 
Millipore, Billerica, MA) membranes using an electrophoretic transfer system (BioRad, 
Hercules, CA). Blots were blocked with 5% powdered milk, and then incubated with 
individual primary antibodies (anti-CRF, anti-CRFR1R or anti-CRFR2R, 1:500) overnight at 
4°C followed by incubation with the secondary antibody (donkey anti-goat IgG-HRP, 
1:2000) for 1 h at room temperature. Tris-buffered saline with 1% Tween-20 was used to 
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wash the blots 3 times (10 min each) after incubation with both primary and secondary 
antibodies. β-actin was used as a gel loading control for the tissue homogenates.  The 
blots were developed with enhanced SuperSignal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL). Immunoreactive bands were visualized and detected on 
polyvinylidene difluoride membrane and analyzed by LabWorks 4.5 software on a UVP 
Biospectrum Imagining System (UVP, Upland, CA). 
Table 2. Antibodies used for western blot. 
Antibody Source Dilution 
anti-CRF Goat 1 500 
anti-CRFR1 Goat 1 500 
anti-CRFR2 Goat 1 500 
donkey anti-goat IgG-HRP Donkey 1 2000 
 
Immunocytochemistry 
 The detailed procedures for immunocytochemistry were described previously (Lei 
et al., 2007, Deng and Lei, 2008, Deng et al., 2009, Xiao et al., 2009a, Deng et al., 
2010a). Briefly, rats (18-day-old) were anaesthetized with pentobarbital sodium (50 
mg/kg) and then perfused transcardially with 0.9% NaCl followed by 4% 
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). Brains were rapidly 
removed and postfixed in the same fixative for an additional 2 h. After postfixation, 
brains were cryoprotected with 30% sucrose in PBS for 12 h and then cut into 20 µm 
slices in thickness horizontally in a Leica cryostat (CM 3050 S) at −21°C. Slices were 
washed in 0.1 M PBS and then treated with 0.3% hydrogen peroxide (HR2ROR2R) for 30 
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minutes to quench endogenous peroxidase activity. After being rinsed in 0.1 M PBS 
containing 1% Triton X-100 and 1.5% normal donkey serum for 30 min, slices were 
incubated with the primary antibodies (goat anti-CRF antibody, sc-1761; anti-CRFR1R 
antibody, sc-12381; anti-CRFR2R antibody, sc-20550; Santa Cruz Biotechnology Inc.) at a 
dilution of 1:100 at 4°C for 12 h. Slices were incubated at room temperature with 
biotinylated donkey anti-goat IgG (ABC Staining System, Santa Cruz Biotechnology 
Inc.) for 1 h and then with avidin-biotin complex (ABC Staining System) for 30 min. 
After each incubation, slices were then washed three times for a total of 30 min. 
Diaminobenzidine (ABC Staining System) was used for a color reaction to detect the 
positive signals. Finally, slices were mounted on slides, dehydrated through an alcohol 
range, cleared in xylene and covered with cover-slips. Slides were visualized and 
photographed with a Leica microscope (DM 4000B). We stained 5–6 nonadjacent 
sections and each staining was repeated by using 3 rats. 









 All data were presented as the means ± S.E.M. For statistical analysis of the 
effects of CRF on epileptiform activity, the averages of 3-5 min of the frequency of 
Antibody Source Dilution 
anti-CRF Goat 1 100 
anti-CRFR1 Goat 1 100 
anti-CRFR2 Goat 1 100 
biotinylated donkey anti-goat IgG Donkey 1:100 
 
53 
epileptiform activity before and after the application of CRF were compared. CRF 
concentration-response curves were fitted by the Hill equation: P
 
PI = IRmaxR × 
{1/[1 + (ECR50R/[ligand]) P
n
P]}, where IRmaxR is the maximum response, ECR50R is the 
concentration P
 
Pof ligand producing a half-maximal response, and n is the Hill P
 
Pcoefficient. 
IRhR were determined by subtracting the instantaneous currents (IRInsR) from the steady-state 
currents (IRssR). Student's paired or unpaired t test or analysis of variance (ANOVA) was 
used for statistical analysis as appropriate; P values were reported throughout the text and 
significance was set as P<0.05. N number in the text represents the slices or cells 
examined. 
Chemicals 
 CRF was purchased from American Peptide Company (Sunnyvale, CA). The 
following reagents were products of TOCRIS (Ellisville, MO): K41498, astressin 2B, 
NBI 27914, CP 154526, MDL 12330A, SQ 22536, forskolin, 3,7-dihydro-1-methyl-3-(2-
methylpropyl)-1H-purine-2,6-dione(IBMX), KT 5720, Rp-cAMPS, CGP55845, 
bicuculline, 6,7-dinitroquinoxaline-2,3-dione (DNQX) and 6Tdl 6T-2-amino-5-
phosphonopentanic acid ( 6Tdl 6T-APV). The other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO). 
Antibodies 
 Goat anti-CRF antibody, sc-1761; anti-CRFR1Rantibody, sc-12381; anti-
CRFR2R antibody, sc-20550; Santa Cruz Biotechnology Inc., biotinylated donkey anti-goat 
IgG (ABC Staining System, Santa Cruz Biotechnology Inc.), avidin-biotin complex and 
Diaminobenzidine (ABC Staining System). 
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Table 4.  Signal transduction and ion channel activators and inhibitors. 
Compound Concentration Used Target 
K41498 0.1 µM CRFR2R0T 0Tantagonist 
astressin 2B 0.1 µM CRFR2R0T 0Tantagonist 
NBI 27914 1 µM CRFR1R0T 0Tantagonist 
CP 154526 1 µM CRFR1R0T 0Tantagonist 
CRF6-33 1 µM CRF-BP inhibitor 
MDL 12330A 50 µM AC inhibitor 
SQ 22536 400 µM AC inhibitor 
Forskolin 20 µM AC activator 
IBMX 500 µM PDE inhibitor 
KT 5720 1 µM PKA inhibitor 
Rp-cAMPS 100 µM PKA inhibitor 
ZD7288 100 µM HCN- channel blocker 
 
Animals 
 Sprague-Dawley rats were purchased from Harlan Laboratories. CRFR2R 
homozygous KO mice (Stock number: 010842; Strain name: B6; 129-crhr2 P
tm1jsp
P/J) and 
WT mice (from the same colony) were bought from Jackson Laboratories. This study was 
carried out in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. The protocol was 
approved by the Committee on the Ethics of Animal Experiments of the University of 





Expression of CRF and CRF2 in the EC 
 Since mRNA of CRF receptors has been detected in the EC by in situ 
hybridization (Lovenberg et al., 1995b) we first examined the expression of CRF and 
CRF receptors in the EC of rats using immunocytochemistry and western blot analysis. 
The anatomical location of the EC and the divisions of individual layers in slice of rats 
were described previously (Deng et al., 2007, Xiao et al., 2009a). Strong 
immunoreactivity for CRF (Figure 15 A, upper panel) and CRFR2R (Figure 15C, upper 
panel) were detected in the EC whereas there was no detectable immunoreactivity for 
CRFR1R in the EC (Figure 15B, upper panel). Western blot demonstrates that a band of ~20 
kDa (Figure 15A, lower panel) close to the reported molecular mass of CRF (Lauber et 
al., 1984, Watabe et al., 1991, Saoud and Wood, 1996) and a band of ~63 kDa (Figure 
15C, lower panel) close to the reported molecular mass of CRFR2R (Miyata et al., 1999) 
were detected in the lysate of the EC. The specificities of the antibodies were confirmed 
by preabsorption of the antibodies with their corresponding blocking peptides blocked the 
detection of the bands (Figure 15, lower panel right). Whereas the molecular mass of rat 
brain CRFR1R was found to be 76–80 kDa (Radulovic et al., 1998, Spiess et al., 1998) there 
was no conspicuous band within this range (Figure 15B, lower panel) demonstrating that 
there is no expression of CRFR1R in the EC. Together, these data demonstrate that the EC
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expresses CRF and CRFR2 Rwith no detectable expression of CRFR1 R(Kurada et al., 2014), 




Figure 15.  The 7Tentorhinal7T neurons express CRF and CRFR2R receptors but not CRFR1R 
receptors. 
A: Immunoreactivity for CRF (upper) and detection of CRF by western 
blot (lower). Upper right: high magnification of the region marked in the 
left.  
B: Lack of immunoreactivity (upper) and protein band (lower) for CRFR1R 
receptors.  
C: The entorhinal neurons showed immunoreactivity (upper) for CRFR2R 
receptors and western blot detected a band close to the molecular mass of 




CRF Facilitates Epileptiform Activity Recorded from the EC  
in Horizontal Slices 
 
 We studied the roles of CRF in epilepsy by recording PTX-induced epileptiform 
activity from layer III of the EC in horizontal slices (Figure 16) as described previously 
by Wang et al., stable epileptiform events occurred in ~20 min after bath perfusion of 
PTX (Wang et al., 2013). We therefore began to record basal epileptiform activity after 
perfusion of PTX for ~20 min. In this in vitro slice seizure model, application of CRF 
(0.1 µM) in the perfusion solution significantly increased the frequency of the 
epileptiform activity (n = 7 slices, P<0.001, Figure 16). 
 
 
Figure 16.  CRF increases the frequency of epileptiform activity induced by PTX. 
AR1R: Bath application of CRF increased the frequency of epileptiform 
activity recorded from layer III of the EC in horizontal slices. 
AR2R: Normalized events showing an increase in epileptiform events after 
the application of CRF 
 Control : 100 µM PTX in aCSF, CRF : Control + 0.1 µM CRF,  




CRF facilitates epileptiform activity recorded from the EC  
in mini-slices 
 
 The above experiments were performed in the horizontal slices containing the EC, 
hippocampus and other cortices. Whereas the connections among the EC and other brain 
regions such as the hippocampus are unlikely to be complete after cutting of the slices, 
we still tested whether the effects of CRF on epileptiform activity were due to the action 
of CRF on structures other than the EC. We therefore cut the medial EC out under a  
microscope and recorded PTX-induced epileptiform activity from layer III of the EC in 
this “mini slice” (Figure 17). 
 
Figure 17.  Micrograph of the mini-slice.  
 
 As shown in Figure 18 AR1R-AR2R, bath application of CRF (0.1 µM) still 
significantly increased the frequency of the epileptiform activity in the mini slices (n = 8, 
P = 0.001, Figure. 18 AR1R-AR2R) excluding the possibility that the action site of CRF is 
outside of the EC. Because CRF-induced increase in epileptiform activity recorded from 
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the horizontal slices was statistically indistinguishable from that recorded from the mini 
slices, (P = 0.98, two-way ANOVA), we used the horizontal slices for the rest of the 
 
Figure 18.  CRF increases the frequency of epileptiform activity induced by PTX in 
mini-slices. 
AR1 R: Bath application of CRF increased the frequency of epileptiform 
activity recorded from layer III of the EC in “mini slices” for which the 
hippocampus and other cortices were cut away. 
AR2R Normalized events showing an increase in epileptiform events after the 
application of CRF.in “mini slices”  
B: Concentration-response curve of CRF-induced facilitation of 





experiments simply for the convenience of experiments. The ECR50 Rfor CRF was measured 
to be 19.6 nM Figure. 18B. Because the maximal effect of CRF could be observed at 0.1 
µM, we used this concentration of CRF for the rest of experiments. 
 
CRF Facilitates the Susceptibility of Epilepsy in the EC 
 We then tested whether CRF facilitates the susceptibility of epilepsy. Bath 
application of the subthreshold concentration of PTX (10 µM), instead of 100 µM PTX, 
used in previous experiments, for 30 min did not induce epileptiform activity (Figure 19. 
AR1R-AR2R), but subsequent co-application of CRF (0.1 µM) induced robust epileptiform 
activity (Figure 19. AR1R-AR2R), suggesting that CRF increases the susceptibility of epilepsy. 
 
 
Figure 19.  CRF facilitates the susceptibility of epilepsy. 
AR1R: Bath application of subthreshold concentration of PTX (10 µM) for  
30 min failed to induce epileptiform activity whereas co-application of 
CRF induced robust epileptiform activity. 
AR2R: Normalized events showing CRF induced epileptiform activity in the 




Endogenously Released CRF Facilitates Epileptiform Activity 
 The above results suggest that endogenously released CRF may play a role in 
epileptogenesis. As shown in Figure 15A, high density of CRF immunoreactivity was 
detected in the EC. Since there is evidence that the neuronal release of neuropeptides 
requires higher stimulation frequencies than that required by monoamine 
neurotransmitters colocalized in the same neuron (Lundberg and Hokfelt, 1983, Consolo 
et al., 1994)  we hypothesized that PTX (100 µM)- induced epileptiform activity that may 
have increased CRF release, which further facilitates the epileptiform activity. We 
therefore tested this hypothesis by probing the roles of endogenously released CRF in 
PTX-induced epileptiform activity. Because CRF binds to the CRF-BP which buffers the 
amount of free CRF in the extracellular compartment (Jahn et al., 2005), we superfused 
slices with CRF6-33 (1 µM), a comparative inhibitor of the CRF-BP   This peptide was 
used successfully to test the endogenous role of CRF in facilitating intracellular Ca P
2+
P 
release in midbrain dopamine neurons (Riegel and Williams, 2008). Bath application of 
CRF6-33 significantly increased the frequency of epileptiform activity induced by PTX 
(236±39% of control, n = 4, P = 0.04, Figure 20 AR1R-AR2R). As will be shown below, CRF-
mediated increases in epileptiform activity were mediated by activation of CRFR2R 
receptors. Pre-incubation of slices with and continuous bath application of the selective 
CRFR2R antagonist, K41498 (0.1 µM) blocked CRF6-33-induced augmentation of 
epileptiform activity (98±9% of control, n = 5, P = 0.82, Figure 20 B). These data 
together demonstrate that endogenously released CRF facilitates epileptiform activity. 
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CRF Increases Epileptiform Activity via Activation of CRF2 Receptors 
 We next probed the roles of the receptors and the signaling mechanisms 
involved in the CRF-mediated facilitation of epileptiform activity, using various 
pharmacological challenges (Figure 21, Table 5). In order to overcome the problem of 
non-specificities of the inhibitors used in the blockade of the signaling cascade, we took 
care of the following parameters: i). Used more than one type of the inhibitor ii). 
Carefully chose the effective concentrations and ICR50R values of the inhibitors given in the 
literature. iii).To ensure pharmacological effectiveness, we pre-treated the slices with the 
inhibitors as described in the literature prior to the application of CRF. Pretreatment of 
slices with and continuous bath application of K41498 (0.1 µM), a CRFR2R antagonist, 
significantly reduced CRF-induced increases in epileptiform activity (122±10% of 
control, n = 11 slices, P<0.001 vs. CRF alone, Figure 22 A). Application of astressin 2B 
(0.1 µM), another CRFR2R antagonist, in the same fashion blocked CRF-induced increases 
in epileptiform activity (113±9% of control, n = 7, P = 0.22 vs. baseline, Figure 22 B). 
We further confirmed the role of CRFR2R receptors by using CRFR2R receptor KO mice. 
Application of CRF (0.1 µM) increased the epileptiform activity in WT mice (n = 14 
slices from 4 mice, P<0.001, Figure 22 C) but did not facilitate the epileptiform activity 
in CRFR2R receptor KO mice (n = 12 slices from 3 mice, P = 0.59, Figure 22 D) further 




Figure 20.  Endogenously Released CRF Facilitates Epileptiform Activity..  
AR1R-AR2R: Bath application of CRF6-33, a comparative inhibitor of the CRF-
binding protein, significantly increased the frequency of epileptiform 
activity via activation of CRFR2R receptor s.  
B: Pre-application of K41498, a selective CRFR2R antagonist, blocked  





Adopted from : Holmes, A. et al., Trends Pharmacol Sci 24 (11), 580 (2003) 









































































(Ruhmann et al., 
1998b, Lawrence et 
al., 2002) 
 
a. Binding data represent Ki values (inhibition constants) at rat or human CRF 
receptors as reported in the associated table reference, unless otherwise indicated. 
b.50% inhibitory binding concentrations (ICR50R) from 0T 0T (Rivier et al., 2002a) using 









sauvagine as the competitive radio ligand. 




















AC Inhibitor (Guellaen et al., 1977, 
Hunt and Evans, 1980, 
van Rossum et al., 2000) 
SQ 22536 9-(Tetrahydro-2-furanyl)-9H-purin-
6-amine 
AC Inhibitor (Harris et al., 1979, 
Fabbri et al., 1991, 








AC Activator (Awad et al., 1983, 
Seamon et al., 1983, 
Laurenza et al., 1989, 
Kim et al., 2005) 
IBMX 3,7-Dihydro-1-methyl-3-(2-
methylpropyl)-1H-purine-2,6-dione 
PDE Inhibitor (Freitag et al., 1998, 
Lepski et al., 2013) 






carboxylic acid, hexyl ester 
PKA Inhibitor (Kase et al., 1987, 
Gadbois et al., 1992, 
Cabell and Audesirk, 
1993) 
Rp-cAMPs (R)-Adenosine, cyclic 3',5'-
(hydrogenphosphorothioate) 
triethylammonium 
PKA Inhibitor (Van Haastert et al., 
1984, Rothermel and 
Parker Botelho, 1988, 
Dostmann et al., 1990, 
Fu et al., 2008) 
ZD 7288 [4-(N-Ethyl-N-phenylamino)-1,2 
dimethyl-6-(methylamino) 






(BoSmith et al., 1993, 
Harris and Constanti, 
1995, Green et al., 1996, 







Figure 22.  CRF facilitates epileptiform activity via activation of CRF R2R receptors. 
A: Pretreatment of slices with and continuous bath application of K41498, 
a selective CRFR2R antagonist, blocked CRF-mediated increases in 
epileptiform activity. 
B: Pretreatment of slices with and continuous bath application of  
astressin 2B, another selective CRFR2R antagonist, blocked CRF-mediated 
increases in epileptiform activity.  
C: Application of CRF increased epileptiform activity in WT mice.  
D: Application of CRF did not induce an increase in epileptiform activity 
in CRFR2R KO mice. 
 
 Whereas these data demonstrate the requirement of CRFR2R receptors, we also 
examined the roles of CRFR1R receptors. CRF-induced increases in epileptiform activity 
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were not altered significantly (vs. CRF alone) in slices treated with NBI 27914 (1 µM, n 
= 8,6TP6T= 0.78, 0TFigure 23 A0T) or CP 154526 (1 µM, n = 12, 6TP6T= 0.87, Figure 23 B), two 
selective CRFR1 Rantagonists.  
 
Figure 23.  CRF-mediated facilitation of epileptiform activity does not involve CRFR1R 
receptors.  
A: Pretreatment of slices with and continuous bath application of  
NBI 27914, a selective CRFR1R antagonist, failed to alter significantly CRF-
mediated increases in epileptiform activity.  
B: Pretreatment of slices with and continuous bath application of  
CP 154526, another selective CRFR1R antagonist, did not change the 
facilitatory effect of CRF on epileptiform activity. 
 
Roles of the AC/cAMP/PKA Pathway in CRF-Induced  
Increases in Epileptiform- Activity 
 
 Because CRFR2R receptors are coupled to AC/cAMP/PKA pathway and there is 
strong evidence demonstrating that cAMP and PKA signals exert a tonic control of 
epilepsy (Boulton et al., 1993, Yechikhov et al., 2001, Higashima et al., 2002, Vazquez-
Lopez et al., 2005, Ure and Altrup, 2006, Ristori et al., 2008), we tested the roles of this 
pathway in CRF-mediated facilitation of epileptiform activity (Figure 24). Slices were 
pretreated with the selective AC inhibitor MDL 12330A (50 µM) for ~20 min and the 
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same concentration of MDL 12330A was included in the PTX-containing extracellular 
solution and applied in the bath before and during the application of CRF. In this 
condition, bath application of CRF (0.1 µM) did not significantly increase the frequency 
of the epileptiform activity (n = 11, P = 0.14, Figure 24 A). Similarly, application of  
SQ 22536 (400 µM), another AC inhibitor, in the same fashion also blocked CRF-
mediated facilitation of the frequency of epileptiform activity (n = 7, P = 0.2, Figure 24 
B). These data together indicate that CRF increases epileptiform activity via activation of 
AC. Activation of AC increases the generation of cAMP. We next tested whether 
elevation of cAMP level mimics the effect of CRF. Bath application of forskolin  
(20 µM), an AC activator, significantly increased the frequency of epileptiform activity 
(170±12% of control, n = 13, P<0.001, Figure 24 C). Moreover, application of IBMX 
(500 µM), a phosphodiesterase (PDE) inhibitor to inhibit the degradation of cAMP, also 
significantly increased the frequency of epileptiform activity (253±23% of control, n = 
15, P<0.001, Figure 24 D). These data together demonstrate that CRF-induced increases 
in the frequency of epileptiform activity are related to an increase in intracellular cAMP 
level. 
 We next tested the roles of PKA in CRF-induced facilitation of epileptiform 
activity. Slices were pretreated with the selective PKA inhibitor KT 5720 (1 µM) for ~20 
min and the same concentration of KT 5720 was included in the PTX-containing 
extracellular solution and applied in the bath before and during the application of CRF. In 
this condition, bath application of CRF (0.1 µM) induced a statistically smaller increase 
in the frequency of epileptiform activity (130±8% of control, n = 10, P = 0.005 vs. CRF 
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alone, Figure 25 A). Application of Rp-cAMPS (100 µM), another specific PKA 




Figure 24.  CRF facilitates epileptiform activity via activation of AC/cAMP pathway. 
A: Pretreatment of slices with MDL-12330A, a selective AC inhibitor, 
blocked CRF-mediated increases in epileptiform activity. 
B: Pre-application of SQ-22536, another AC inhibitor, blocked CRF-
mediated facilitation of epileptiform activity.  
C: Bath application of forskolin, an AC activator, increased the frequency 
of epileptiform activity. 
D: Bath application of IBMX, a PDE inhibitor, enhanced the frequency of 




the frequency of epileptiform activity (133±4% of control, n = 9, P = 0.004 vs. CRF 
alone, Figure 25 B). These data together demonstrate that PKA also plays a role in CRF-
mediated increase in epileptiform activity. 
 
 
Figure 25.  CRF facilitates epileptiform activity via partial involvement of PKA 
pathway.  
A: Pretreatment of slices with KT 5720, a selective PKA inhibitor, 
partially blocked CRF-mediated enhancement of the frequency of 
epileptiform activity.  
B: Pretreatment of slices with Rp-cAMPS, another specific PKA inhibitor 
partially blocked the facilitatory effect of CRF on epileptiform activity. 
 
Roles of HCN-Channels in CRF-Mediated Facilitation of Epileptiform Activity 
 We tested whether HCN channels, in general, are involved in CRF-induced 
facilitation of epileptiform activity for the following reasons. First, CRF has been shown 
to facilitate HCN-channels (Qiu et al., 2005a, Wanat et al., 2008, Giesbrecht et al., 2010). 
Second, entorhinal neurons express robust HCN-channels (van der Linden and Lopes da 
Silva, 1998, Dickson et al., 2000). Third, HCN-channels are involved in epilepsy in other 
regions of the brain (Huang et al., 2009, Noam et al., 2011). Bath application of the 
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selective HCN-channel blocker, ZD 7288 (100 µM) significantly reduced the frequency 
of epileptiform activity to 54±7% of control (n=9, P<0.001, Figure 26 A, B) and bath 
application of CRF in the presence of ZD 7288 did not further elevate the frequency of 
epileptiform activity (53±12% of the base line before the application of ZD 7288, n=9, 
P=0.94 vs. ZD 7288 alone, Figure 26 A, B). These data suggest a role for HCN-channels 
in CRF-induced facilitation of epileptiform activity.  
However, further analysis by measuring the numbers of synchronizing events, 
reminiscent of the interictal activity (between-seizures),  in single ictal (seizure)-like 
epileptiform discharges and the duration of individual epileptiform activity demonstrated 
that ZD 7288 significantly increased the numbers of synchronizing events in single 
epileptiform activity (322±59% of control, n=9, P=0.009, Figure 26 A) and the duration 
of individual epileptiform activity (230±34% of control, n=9, P=0.002, Figure 26 A) 
suggesting that HCN-channels alter the patterns of epileptiform activity. In the presence 
of ZD 7288, bath application of CRF further increased the number of synchronizing 
events in single epileptiform activity (568±92% of control, n=9, P<0.001 vs. ZD 7288 
alone, Figure 26 C) and the duration of individual epileptiform activity (366±62% of 
control, n=9, P=0.008 vs. ZD 7288 alone, Figure 26 C). These data suggest that CRF 
facilitates epileptiform activity via multiple mechanisms and HCN-channels contribute to 
but are not the sole performer in CRF-mediated facilitation of epilepsy.  
 If HCN-channels are involved in CRF-mediated facilitation of epileptiform 





Figure 26.  HCN channels are involved in CRF-mediated facilitation of epileptiform- 
activity.  
A: Epileptiform activity recorded from a slice in response to sequential 
applications of ZD 7288 and CRF. Arrows indicate the expansion of a 
single epileptiform activity. Note the difference of the time in the scale 
bar.  
B: Summarized time course of the frequency of the epileptiform activity in 
response to the sequential applications of ZD 7288 and CRF. Note that 
application of ZD 7288 significantly reduced the frequency of 
epileptiform activity and application of CRF in the presence of ZD 7288 
failed to further increase the frequency of epileptiform activity.  
C: Summarized data for the number of synchronizing events in individual 
epileptiform activity and the duration of single epileptiform activity in 
response to ZD 7288 and CRF. Data were normalized to the control level 
before application of ZD 7288. Note that CRF still increased the number 
of synchronizing events in single epileptiform activity and the duration of 





 We next tested whether CRF modulates HCN-channel function by recording IRhR 
from the stellate neurons in layer II of.the EC, because these neurons express robust 
HCN-channels (van der Linden and Lopes da Silva, 1998, Dickson et al., 2000) 
Stellate Neuron Identification: 
  
Figure 27.  Stellate neuron identification.  
A: Schematic illustration of the recording location in the EC. DG, dentate 
gyrus; Sub, subiculum; PER, perirhinal; R, recording electrode.  
B: a stellate neuron identified under an infrared video microscopy.  
C: voltage responses (top) generated by current injection from + 0.4 to  
-1 nA at an interval of -0.1 nA (bottom) recorded from a stellate neuron in 




 mEC layer II neurons were visually identified using infrared video microscopy 
(Olympus BX51W1) and differential interference contrast optics. About 70% of the 
neurons in layer II of the mEC are stellate neurons (Klink and Alonso, 1997). A 
schematic illustration of the EC appears in 15TFigure 27.  
 Stellate neurons are the most numerous class of excitatory neurons in layer II. 
These neurons are usually located in layer II or the border of layer II and III, and they 
have distinct “star like” morphology with a larger and polygonal soma and a variable 
number of main dendrites radiating out from the cell body but are devoid of a clearly 
dominant dendrite (Deng and Lei, 2007) (Figure 27) These neurons have unique 
electrophysiological properties; i.e., hyperpolarizing current pulse injection always 
caused the membrane potential to attain an early peak and then “sag” to a steady-state 
level (Alonso and Klink, 1993, Deng and Lei, 2007). 
CRF Augments HCN-Channel Currents in Layer II Stellate Neurons 
 Because we initially found that IRhR recorded by whole-cell configuration 
underwent significant run-down, we used perforated-patch recordings (Figure 28). Cells 
were held at -50 mV and a series of hyperpolarizing voltages (from -50 mV to -130 mV 
at an interval of 10 mV) were applied for 1 s to record the voltage-current relationship 
before and after the application of CRF (Figure 28A). A single voltage step (from -50 mV 
to -130 mV) was applied every 20 s to measure the time course of IRhR in response to CRF 
application (Figure 28 C). At the end of experiments, ZD 7288 (100 µM) was applied to 
corroborate the identity of the recorded IRhR (Figure 28). Under these circumstances, bath 
application of CRF (0.1 µM) significantly increased IRhR (133±8% of control, n=9, 




Figure 28.  CRF enhances IRhR recorded from layer II stellate neurons in perforated-
patch recordings.  
A: IRhR recorded by hyperpolarizing to different voltages from the holding 
potential of -50 mV for 1 s at an interval of 10 mV before (left) and after 
(middle) application of CRF. Application of ZD 7288 (100 µM) at the end 
of the experiments blocked IRhR.  
B: Voltage-current relationship before and after the application of CRF. * 
P<0.05, ** P<0.01.  
C: Time course of IRhR recorded by hyperpolarizing from -50 mV to  
-130 mV before, during and after the application of CRF. Application of  
ZD 7288 at the end of the experiments completely blocked Ih. Inset shows 
the current traces recorded at different time points indicated in the figure. 
 
We further determined the effects of CRF on the voltage-sensitivity of IRhR conductance. IRhR 
conductance (GRHR) was determined as the amplitude of IRhR measured at different potentials 
(V) divided by the driving force (V-ERHR), where ERHR is the reversal potential of IRhR. The 
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value of ERHR was arbitrarily set at -35 mV, which represents the median ERHR reported in a 
variety of cell types (Ghamari-Langroudi and Bourque, 2000). The GRHR at different 
voltages were normalized to the maximal GRHR and plotted versus the voltages. The 
voltage-conductance relationship was fit by the equation GRH(V)R = 1/(1+eP
-k(V-V1/2)
P), where 
GRH(V)Ris the fraction of maximal GRHR observed at individual voltage, k is the slope factor 
and VR1/2 Ris the half-maximal voltage. CRF shifted the VR1/2R by 5.7±1.4 mV (n=9, P=0.004) 
to a more depolarized potential (Figure 29 A). CRF slightly but significantly altered the 













Figure 29.  Effects of CRF on the voltage-sensitivity of IRh.Rconductance  
A: Voltage-conductance relationship before and after the application of 
CRF.  
B: Summarized VR1/2 R(left) and k (right). The open symbols represent the 
values for individual cells and the solid symbols indicate the averages. 
CRF slhifted the VR1/2 Rto more depolarized potential and slightly, but 
significantly altered the slope factor (k). 
 
 We then tested the involvement of CRFR2R receptors in CRF-induced increases in 
IRhR. Bath application of the selective CRFR2R antagonist, K41498 (0.1 µM), blocked CRF-




Involvement of cAMP Not PKA in CRF-Mediated  





Figure 30.  CRF augments IRhR via activation of CRFR2R receptors.  
AR1R-AR2R: Application of CRF in the presence of CRFR2R antagonist, K41498, 
failed to increase IRhR.  
BR1R-BR2R: CRF did not enhance IRhR in slices cut from CRFR2R knockout mice.  
CR1R-CR2R: Application of CRF increased IRhR in slices cut from wild-type mice. 
 
 Furthermore, CRF did not increase IRhR in slices cut from CRFR2R knockout mice 
(n=9 cells from 3 mice, P=0.27, Figure 30 BR1R-BR2R) whereas CRF still significantly 




 CRFR1R antagonist, NBI 27914 (0.1 µM) still significantly augmented IRhR (n=9, 
P=0.009, Figure 31 AR1R-AR2R). These data together indicate that CRF increases IRhR via 





Figure 31. CRFR1 Rreceptors are not involved in Ih increase. 
AR1R-AR2R: Application of CRF in the presence of CRFR1R antagonist,  
NBI27914, still augmented IRhR. 
 
 We further probed the roles AC/cAMP/PKA pathway in CRF-induced increases 
in IRhR in layer II stellate neurons. CRF-induced increases in IRhR were blocked by application 
of MDL 12330A (50 µM, 107±4% of control, n=7, p=0.15, Figure 32 AR1R-AR2R) and 
SQ 22536 (400 µM, 104±2% of control, n=5, P=0.14, Figure 32 BR1R-BR2R) indicating that 
CRF- mediated facilitation of IRhR requires the functions of AC and cAMP. However, 
application of CRF still augmented IRhR in the presence of Rp-cAMPS (100 µM, 150±21% 
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of control, n=6, P=0.008, Figure 32 CR1R-CR2R) and KT 5720 (1 µM, 127±3% of control, 
n=5, P=0.026, Figure 32 DR1R-DR2R) demonstrating that CRF-induced increases in IRh Ris 
independent of PKA activity. 
 
 
Figure 32.  CRF-induced enhancement of IRhR is mediated by cAMP but not by PKA. 
AR1R-AR2R: Application of CRF in the presence of AC inhibitor,  
MDL 12330A, failed to increase IRhR significantly.  
BR1R-BR2R: CRF did not enhance IRh Rin the presence of another AC inhibitor,  
SQ 22536.  
CR1R-CR2R: Application of CRF in the presence of Rp-cAMPS still increased 
IRhR.  
DR1R-DR2R: Application of KT 5720, another PKA inhibitor, failed to block 




CRF Increases AP Firing Frequency in Layer II Stellate Neurons of the EC 
 We then tested the effect of CRF on neuronal excitability by recording AP firing 
from the layer II stellate neurons. Bath application of CRF (0.1 µM) for 7 min. 
significantly increased the firing frequency of these neurons (control: 1.06 ± 0.16 Hz; 
CRF: 3.69 ± 0.44 Hz; n = 7; P = 0.001; Figure 33), and the firing frequency was 
sustained even during the wash, after the application of CRF was stopped. 
 
 
Figure 33. Bath application of CRF increased the firing frequency of APs recorded 
from layer II stellate neurons in EC. 
AR1R: APs recorded prior to, during, and after application of CRF (0.1 μM). 
AR2R: time course of CRF-induced increases in AP firing frequency (n = 7). 
 
CRF Causes Increase in Inward HCs 
 We next examined the effects of CRF on the inward holding current, in voltage-
clamp mode, CRF induced an inward shift of the HCs recorded at −60 mV (−37.1 ± 3.1 


























































 A number of brain regions including the hippocampus, the amygdala and the EC 
are involved in the epileptogenesis. However, the cellular and molecular mechanisms are 
still not well established. The EC is an important limbic structure involved in the 
development, maintenance and spread of seizures in the patients with TLE and in 
epileptic animal models (Spencer and Spencer, 1994, Gloveli et al., 1998, Avoli et al., 
2002, Avoli and de Curtis, 2011). Studies show that the EC is more susceptible to 
seizures than the hippocampus. EC is a six-layered structure and functions as a gateway 
to the hippocampus and other cortical regions (Witter et al., 1989, 2000). The current 
study focuses on layers II and III for the following reasons: The layer III pyramidal 
neurons are hyperactive in vivo after the induction of TLE, and thus play a critical role of 
epileptogenesis. Layer III neurons are preferentially lost in both human TLE (Kim et al., 
1990, Du et al., 1993) as well as animal models of epilepsy (Du and Schwarcz, 1992, Du 
et al., 1995). With the onset of epilepsy and loss of CA3 neurons and the SC pathway 
(Ben-Ari and Cossart, 2000), the TA pathway has been suggested as a major excitatory 
drive to the principal neurons of the CA1 region (Barbarosie et al., 2000, Avoli et al., 
2002, Wu and Leung, 2003). Thus altered pyramidal cell excitability in the layer III of 
the EC is likely to have a greater impact in the development of TLE. The neurons of
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layer II are well spared and become hyperexcitable (Bear et al., 1996) due in part to a 
reduction in inhibitory input (Kobayashi and Buckmaster, 2003), and proexcitatory 
alterations in sodium channel gating parameters (Hargus et al., 2011).Thus layer II cause 
an excitatory drive into the DG and the hippocampus (Buckmaster and Dudek, 1997) 
resulting in seizure induction and propagation. Hence mEC layer II neurons can be a 
potential site of action of AEDs to suppress neuronal excitability or to reduce the seizure 
activity once fully evoked (Hosseinmardi et al., 2007).  
 A number of factors can precipitate seizures in patients with epilepsy (Spector et 
al., 2000), and stress is amongst the most common triggering factors (Lai and Trimble, 
1997, Frucht et al., 2000, Haut et al., 2003, Nakken et al., 2005, Haut et al., 2007, 
Sperling et al., 2008). Epileptic patients show a dysregulation in the HPA axis (Zobel et 
al., 2004, Mazarati et al., 2009) and increased basal levels of stress hormones, which 
further increase after seizures (Abbott et al., 1980, Pritchard et al., 1985, Culebras et al., 
1987, Galimberti et al., 2005). CRF is a 41 amino acid neuropeptide initially isolated by 
Vale and his colleagues (Vale et al., 1981), a hypothalamic factor which activates the 
HPA axis, initiating the release of ACTH from the pituitary, which in turn causes the 
release of glucocorticoids from the adrenal cortex, to regain homeostasis (Dunn and 
Berridge, 1990). CRF mediates the endocrine, autonomic, and behavioral responses to 
stress (Aldenhoff et al., 1983, Ehlers et al., 1983, Siggins et al., 1985, Swanson et al., 
1986, Conti and Foote, 1995, Sawchenko et al., 1996, Baram and Hatalski, 1998).  
Supporting evidence from various studies using immunolabeling, radioimmunoassay, and 
mRNA expression have demonstrated that CRF is widely distributed in brain areas of., 
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human (Charlton et al., 1987), rat (Fischman and Moldow, 1982), and mouse(Nakane et 
al., 1986). In addition to the PVN of  the hypothalamus, CRF-containing neurons are also 
found in various other brain regions, and is highly expressed in areas associated with 
developmental seizures, such as the hippocampus and the amygdala (Gray and 
Bingaman, 1996, Yan et al., 1998);(Steckler and Holsboer, 1999). The extra-
hypothalamic source of CRF has been demonstrated by central administration of CRF 
which caused anxiety-like behavioral and autonomic effects (Britton et al., 1982, Dunn 
and File, 1987, Koob and Heinrichs, 1999) and these behaviors persisted in 
hypophysectomized rats (Eaves et al., 1985). Abnormalities in the HPA- and the extra-
HPA axis-CRF homeostasis have been documented with e 0Tpilepsy. 0TCRF transduces its 
effects via two B-type G-protein coupled receptors CRFR1R and CRFR2R, which show 70% 
homology (Perrin and Vale, 1999). Free levels of CRF are maintained in the brain as well 
as periphery by a binding protein called CRF-BP. Both the receptors and the binding 
protein have distinct pharmacological profiles (De Souza, 1995, Gulyas et al., 1995, 
Dautzenberg and Hauger, 2002, Chatzaki et al., 2006, Fekete and Zorrilla, 2007), and are 
distinctly and differentially distributed throughout the brain (Steckler and Holsboer, 
1999). Various animal models revealed that intracerebroventricular injection of CRF 
induces seizures (Ehlers et al., 1983, Marrosu et al., 1987, Marrosu et al., 1988, Weiss et 
al., 1993) and the levels of CRF and CRF-BP are increased in patients as well as animals 
models of epilepsy.Despite of the tremendous amount of studies relating the EC and CRF 
in mediating epilepsy, not much is known about the role and relevance of CRF in the EC.  
 
86 
 Based on the available information that CRF, CRFRs and CRF-BP mRNA was 
shown in various regions including the EC, our overarching hypothesis of this project 
was that CRF in the EC binds to its receptors and facilitates epilepsy. To begin to test this 
hypothesis, we initially wanted to examine the presence of CRF and the type of receptors 
in EC, using immunocytochemsitry and western blot techniques. While strong 
immunoreactivities were detected for CRF and CRFR2, Rthere was no detectable 
immunoreactivity for CRFR1R. These results were further corroborated by westernblot. The 
reported masses for CRF, CRFR2R and CRFR1R are, ~20 kDa (Lauber et al., 1984, Watabe et 
al., 1991, Saoud and Wood, 1996) ,~63 kDa (Miyata et al., 1999) and 76–80 kDa 
(Radulovic et al., 1998, Spiess et al., 1998) respectively. While bands closer to the above 
respective molecular mass were observed for both CRF and CRFR2R, no conspicuous band 
was observed for CRFR1R. These results demonstrated that both CRF protein and CRFR2  
Rreceptors are predominantly expressed in the EC (Kurada et al., 2014), as shown in 
previous in situ hybridization studies (Lovenberg et al., 1995b), suggesting that CRF 
plays an important role in the EC.  
 A number of studies have shown CRF to be a potent epileptogenic molecule and 
CRF contributes to increased excitation in limbic regions. For example, 
intracerebroventricular injections of CRF produces spontaneous seizures (Ehlers et al., 
1983, Weiss et al., 1986b, Marrosu et al., 1988, Baram and Schultz, 1991b). CRF-
induced epileptiform activity is initiated in the amygdala which then spreads to other 
brain regions (Baram et al., 1992). Since our previous results indicate the presence of 
CRF and its receptor, we then wanted to explore whether CRF facilitates epileptiform 
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activity in the EC. A number of in vitro and in vivo models of epilepsies have been 
developed to study the mechanisms underlying different types of epilepsies. Various 
chemical convulsants are commonly used such as, PTX, Pentylenetetrazol, pilocarpine 
and kainic acid. These drugs generally act by interfering the normal synaptic transmission 
(Kupferberg, 2001) .Here we used a well-established in vitro model called PTX-slice 
seizure model. The PTX-induced seizure model resembles the simple partial and 
generalized forms of human epilepsy (Fisher, 1989, Sierra-Paredes and Sierra-Marcuno, 
1996, Sarkisian, 2001). PTX blocks the chloride channels linked to GABARAR-receptors 
and thereby prevents the conductance of chloride ions into the neuronal membrane. This 
result in the inhibition of GABA neurotransmission and GABA mediated inhibition of 
neuronal activity and thereby elicits seizures (Orhan et al., 2012). Using PTX (100 µM) 
in the acsf, epileptiform activity was induced. Extracellular field recordings were 
obtained from layer III of the EC, in the horizontal hippocampus-entorhinal slices After 
stable events, basal or control epileptiform activity was recorded and then CRF (0.1 µM) 
was applied. Electrophysiological measurements showed that application of CRF to the 
entorhinal slices robustly increased the frequency of epileptiform activity induced by 
PTX. The CRF-mediated epileptiform activity was sustained even during wash, after the 
application of CRF (Kurada et al., 2014), indicating that CRF is triggering a cascade of 
signaling events resulting in possible receptor and/or channel up regulation. Our results 




 The above experiments were conducted in the horizontal slices containing the EC, 
hippocampus and other cortices. Although it was unlikely that the connections among the 
EC and other regions to be complete after cutting the slices, it might be possible that the 
action site of CRF could likely be in the other brain regions other than the EC. In order to 
confirm whether the action site is the EC, we recorded from the ‘mini’ slices in which 
other brain regions except the mEC were cut off. CRF still induced the same level of 
facilitation of PTX-induced epileptiform activity (Kurada et al., 2014). These results 
together demonstrate that CRF acting in the EC can facilitate epileptiform activity. Since 
CRF-mediated increase in epileptiform activity recorded from the horizontal and the 
mini-slice was statistically indistinguishable, horizontal slices were used for the rest of 
experiments, for the sake of convenience. The calculated ECR50R was 19.6 nM. However, 
since the maximal effect was obtained at 0.1 µM, the same concentration was used for the 
rest of our experiments. 
 CRF is known to show pro-convulsant properties. CRF could not elicit seizures 
by itself in infant hippocampus rats (Hollrigel et al., 1998), when CRF is administered 
before amygdala kindling, the time to reach the fully kindled state is markedly reduced 
(Weiss et al., 1986) The proconvulsive role of CRF is further confirmed by studies from 
the Lewis rats, with reduced CRF expression. These rats take longer to kindle and require 
more electrical stimulations (Weiss et al., 1993). Based on these studies, we then wanted 
to test whether CRF by itself can induce epileptiform activity in the EC. In the absence of 
PTX, when CRF was bath applied, CRF could not induce any epileptiform activity. 
However, in the presence of sub-threshold concentration (10 µM) instead of (100 µM) 
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PTX, though the sub-threshold concentration of PTX could not elicit any epileptiform 
activity, application of CRF could produce epileptiform events. These results are in 
agreement with the previous studies showing the pro-convulsant actions of CRF in other 
brain regions. These results corroborate the fact that CRF cannot induce epileptiform 
activity but itself in the EC, but can increase the epileptiform activity induced by PTX.  
 Our next question was regarding the mechanisms by which CRF modulates 
epilepsy. We next wanted to determine the type of receptor, CRFR1R and/or CRFR2, Rinvolved 
in CRF-mediated facilitation of epileptiform activity in the EC. Since our earlier 
experiments showed strong immunoreactivity for CRFR2R, which was further confirmed by 
the western blot, we pretreated slices with antagonists for CRFR2R receptors. In the 
presence of CRFR2R antagonists, CRF-mediated facilitation of epileptiform activity was 
significantly blocked. Multiple antagonists were used to rule out any possibility of 
antagonist non-specificity. The results obtained from the above pharmacological 
challenges were further corroborated by CRFR2R KO mice. When CRF was applied to the 
slices cut from the CRFR2 RKO mice, CRF failed to increase the frequency of epileptiform 
activity. However, CRF still exerted robust facilitatory effects on the frequency of 
epileptiform activity when applied to slices cut from WT mice. Though the above results 
suggest that CRFR2R is predominantly expressed in the EC and facilitates the epileptiform 
activity, it might be possible that CRFR1R receptors were undetected by the methods we 
employed in our experiments, but may still be functionally active. To rule out this 
possibility, we tested the role of CRFR1R in CRF-mediated epileptiform activity. In the 
presence of CRFR1R antagonists, CRF could still significantly augment the frequency of 
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PTX-induced epileptiform events. Furthermore, CRF binds with high affinity to the 
CRFR1R but has low affinity for CRFR2R (Dautzenberg and Hauger 2002). Hence it might be 
possible that CRFR1R receptors, even if present in the EC, might be non-functional. Our 
results have therefore filled a gap for the effects of CRF in the EC by demonstrating that 
CRF-elicited facilitation of epileptiform activity is mediated by CRFR2R receptors. 
 The next question was the role of endogenously released CRF in facilitating 
epileptiform activity in the EC. CRF is released within many other brain regions such as 
the hippocampus, the amygdala (Roozendaal et al., 2002) locus ceruleus (Valentino and 
Wehby, 1988, Snyder et al., 2012). Since CRF can travel to distances longer from the 
regions of origin, within the brain (Bittencourt and Sawchenko, 2000a), it might be 
possible that CRF from extra-entorhinal source which is transported from the distal brain, 
here in this case, the hippocampus and other regions in the horizontal slice, and acts on 
CRFRs in the EC. The levels of free CRF in the extracellular component are regulated by 
the CRF-BP. We then determined the role of endogenously released CRF by the 
application of the CRF-BP antagonist CRF6-33, which also increased the frequency of 
PTX-induced epileptiform activity suggesting that endogenously released CRF is 
involved in epileptogenesis. Thus, the CRF-BP may hold as a reservoir of CRF and 
therefore the regulation of the interaction between CRF and CRF-BP may represent a 
mechanism by which CRF can be released to activate the CRF receptors present in the 
EC. Taken together these results demonstrate that the CRF endogenously released from 
the EC facilitates epileptiform activity via activation of the CRFR2R receptors. 
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 What are the signaling mechanisms by which CRF facilitates epileptiform activity 
in the EC? The biological actions of CRF are likely to be mediated by CRFRs and their 
intracellular signals. Both CRFR1R and CRFR2R are primarily coupled to GRsR proteins, 
activating the AC/cAMP/PKAcascade (Dautzenberg and Hauger, 2002, Grammatopoulos 
and Chrousos, 2002, Hauger et al., 2006). CRFRs also have various degrees of coupling 
competence and potency to interact with other G-protein systems including GRqR, GRiR, GRoR, 
GRi1/2R, and GRzR (Grammatopoulos et al., 2001). Thus CRF can modulate various signaling 
cascades and kinases comprising of protein kinase B (PKB), protein kinase C (PKC), 
mitogen-activated protein (MAP) kinases and intracellular Ca P
2+
P concentrations in a 
tissue-specific and concentration dependent manner (Dautzenberg and Hauger, 2002, 
Grammatopoulos and Chrousos, 2002, Hauger et al., 2006).The AC/cAMP/PKA pathway 
is predominant Gs activated signaling cascade, increasing the neuronal firing. However, 
whether PKA is coupled with the CRF in transducing the epileptiform activity is not 
clear. Elucidating the signal transduction mechanism in the EC, will help in better 
understanding of the etiology of the disease. To elucidate the signaling mechanisms, 
various activators and inhibitors of the cAMP/PKA signaling cascade were used. In order 
to overcome the problem of non-specificities of the inhibitors used in the blockade of the 
signaling cascade, we took care of the following parameters: i). Used more than one type 
of the inhibitor ii). Carefully chose the effective concentrations and ICR50R values of the 
inhibitors given in the literature. iii).To ensure pharamacological effectivesness, we pre-
treated the slices with the inhibitors as described in the literature prior to the application 
of CRF. Activation of CRFR2R receptors increases the function of AC resulting in 
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augmentation of cAMP production and subsequent activation of PKA. We demonstrate 
that AC and cAMP are fully required but PKA may be partially necessary for CRF-
mediated facilitation of epileptiform activity based on the following results. AC is an 
enzyme that converts ATP to cAMP. Hence inhibition of AC should result in blockade of 
CRF-mediated increases in epileptiform activity. To test this, we used AC inhibitors, 
MDL 12330A and SQ 22536. In the presence of these AC inhibitors, CRF-induced 
augmentation of epileptiform activity was completely blocked. Next, elevation of 
endogenous cAMP level should augment epileptiform activity by itself. To test this, we 
used Forskolin, a cAMP activator and IBMX, a PDE inhibitor. PDE is the enzyme that 
degrades cAMP to 5’-AMP and thereby limits the stimulatory effect of the cAMP 
cascade. By inhibiting PDE using IBMX, the levels of cAMP are therefore increased. 
Forskolin and IBMX produced significant increases in epileptiform activity by 
themselves and thus mimic the effects produced by CRF. If PKA is involved in CRF-
mediated increases in epileptiform activity, blocking PKA should block the CRF-
mediated effects. To test this hypothesis, PKA was inhibited by KT 5720 and  
Rp-cAMPS. This resulted in significantly reduced but not completely blocked CRF-
mediated increases in epileptiform activity. In accordance with our results, tremendous 
evidence demonstrates that AC/cAMP/PKA pathway plays a facilitatory role in epilepsy 
(Boulton et al., 1993, Yechikhov et al., 2001, Higashima et al., 2002, Vazquez-Lopez et 
al., 2005, Ure and Altrup, 2006, Ristori et al., 2008).  
 Given the direct link among ion channel activity, neuronal excitability and 
epilepsy, ion channels remain an active area of investigation. What are the ion channels 
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that are involved in CRF-mediated increases in epileptiform activity? Since HCN 
channels play an important role in epilepsy (Huang et al., 2009, Noam et al., 2011) and 
the entorhinal neurons express robust HCN-channels (van der Linden and Lopes da Silva, 
1998, Dickson et al., 2000), we tested the roles of HCN-channels in CRF-mediated 
facilitation of epileptiform-activity. HCN channels maintain the RMP and thus control 
the neuronal excitability. HCN channels are regulated by neurotransmitters and hormones 
that act via cAMP, cGMP, or intracellular Ca P
2+(
P ape 1996); cAMP and cGMP modulate 
HCN channel activity via direct interaction with the cyclic nucleotide-binding domain 
protein of the C-terminus (Ludwig et al. 1998). HCN channels interact with multiple 
neurotransmitter systems and are coupled both positively, via the Gs, and negatively, via 
Gi-proteins, to the cAMP synthesis and thus are up- and down-regulated (Frere and Luthi 
2004; Pape 1996). Since our results show the involvement of cAMP in CRF-mediated 
epileptiform activity, and HCN channels are modulated by cAMP; and the layer II stellate 
neurons express high levels of HCN channels, we wanted to test the role of these 
channels in CRF-mediated facilitation of epilepsy. We then probed the role of HCN-
channels. HCN-channels by themselves exert three effects on picrotoxin-induced 
epileptiform activity. First, application of the selective HCN-channel blocker ZD 7288 
significantly reduced the frequency of the epileptiform activity suggesting that HCN-
channels modulate the rhythm of epilepsy. This is also consistent with the roles of HCN-
channels because HCN-channels are involved in rhythmic modulation of neuronal 
activity. Second, inhibition of HCN-channels results in enhanced number of 
synchronizing events in single epileptiform activity. Third, HCN-channel inhibition also 
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enhanced the duration of individual epileptiform activity. It must be noted that the 
synchronizing events represent the interictal activity, which is a state of continuous 
neuronal excitability; the above results show that CRF modulates the HCN channel 
properties. 
 If CRF plays a role in modulating the HCN channels, CRF should modulate the 
current flowing through these channels as well. HCN channels carry current known as Ih. 
We then wanted to probe the role of IRhR current in CRF-mediated facilitation of 
epileptiform activity. Perforated patch clamp recordings were performed from the layer II 
stellate neurons. Voltage-current relationship revealed that CRF augments Ih. These 
results were further corroborated by the blockade of HCN channels using ZD7288. 
Furthermore, CRF increased the conductance and caused membrane depolarization which 
is indicative of increased neuronal excitability. In order to identify whether CRF 
modulates the Ih current via CRFRs, using selective CRFR2R inhibitors, we found that CRF 
augments IRhR current via CRFR2R receptors. These results were further corroborated using 
CRFR2R KO mice, in which CRF-mediated IRhR increase was blocked. In the presence of 
AC/cAMP blockers, CRF could not facilitate the increases in IRhR, whereas the PKA 
inhibitors have no effect on CRF-mediated IRh Rincrease. This shows that CRF augments IRhR 
via cAMP signaling, but PKAis not required. The result that blockade of HCN-channels 
by ZD 7288 also blocked CRF-mediated increase in the frequency of epileptiform 
activity suggests that HCN channels contribute to CRF-mediated augmentation of 
epileptiform activity. However, we do not consider HCN channels as the sole player in 
CRF-mediated facilitation of epileptiform activity based on the following pieces of 
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evidence. First, the number of the synchronizing events in single epileptiform activity 
after inhibition of HCN-channels by ZD 7288 was still significantly increased after 
application of CRF. Second, the duration of individual epileptiform activity was still 
enhanced by CRF after inhibition of HCN channels by ZD 7288. Third, our results 
suggest that CRF facilitates IRhR via cAMP without requirement of PKA. If HCN channels 
are the only performer, inhibition of PKA should not exert any effects on CRF-mediated 
facilitation of epileptiform activity. However, our results demonstrated that inhibition of 
PKA significantly reduced CRF-mediated enhancement of epileptiform- activity 
suggesting that molecules other than HCN channels are still targets of CRF. Further 
studies will identify other mechanisms underlying CRF-induced facilitation of 
epileptiform activity. 
 CRF is known to induce excitability in cortex and the forebrain (Eberly et al. 
1983), the hippocampus, Purkinje cells, and the dorsal vagal complex is augmented by 
CRF-mediated reductions in afterhyperpolarization (AHP) (Aldenhoff et al. 1983; 
Hollrigel et al. 1998; Lewis et al. 2002; Yamashita et al. 1991).We then wanted to probe 
the role of CRF at the cellular level and the mechanisms involved. When CRF (0.1 µM) 
was applied to the stellate neurons, a significant increase of neuronal firing was produced 
in the presence of CRF and was sustained even when CRF was washed out. Also, CRF 






P channels These results indicate that CRF acts at the neuronal level and increases 
excitability. Further experiments to identify the ion channels and signaling mechanisms 
would help to better understand the role of CRF in the EC. 
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Summary and Significance 
 CRF is an important neuropeptide and involved in various brain functions, and a 
potent epileptogenic neuropeptide. The seizure-facilitating effects of CRF have largely 
been explained based on its actions in various other regions of the brain such as the 
hippocampus and the amygdala. However, the action sites and mechanism of actions of 
CRF are not yet determined. CRF and CRFR immunoreactivity was found in the EC, but 
the role and relevance of CRF in facilitating seizures are not well established. This 
dissertation provides evidence that CRF facilitates epileptiform activity via activation of 
CRFR2R receptors. and cAMP signaling, whereas PKA is partially involved. Endogenously 
released CRF is responsible for the CRF-mediated epileptiform activity, as blockade of 
CRF-BP by a selective antagonist, CRF6-33, significantly increased the epileptiform 
activity. CRF-mediated facilitation of epileptiform activity involved the modulation of 
HCN channels and increases in IRhR current activated via CRFR2R signaling, with the 
involvement of cAMP. PKA was not involved in the enhancement of CRF mediated 
increases in IRhR (Figure 35). Further understanding the mechanisms of pro-convulsant 
effects of CRF within the EC, will provide valuable information for developing targeted 
drug moieties that can reduce the seizure activity.  
 Accumulating evidence suggests that the stress-related hormone CRF and the 
HPA axis play a critical role in the pathophysiology of TLE. CRF facilitates exacerbation 
of neuronal excitability by modulating molecular, structural and synaptic functions 
resulting in decreased seizure threshold and epilepsy. Epilepsy-mediated by stress 
system, especially by CRF and its receptors have important implications for the therapy 
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of patients with TLE. Changes in the molecular composition and function of the CRF 
system and its receptors may alter the modulatory effects of CRF in facilitating epilepsy 
in various brain regions. A deeper understanding of the mechanisms and specific target 
regulation of CRF receptor in regionally distinct roles of the CRF receptors in various 
brain regions would allow specific target receptors in the epileptic neurons and thus 
increasing efficacy and reducing the side effects. Furthermore, certain neuropeptide 
characteristics such as discrete neuroanatomical localization, relatively little disruption of 
normal physiology by the neuropeptide ligands, and the requirement of higher stimulation 
frequencies for the neuronal release of neuropeptides than those required by monoamine 
neurotransmitters and GABA colocalized in the same neuron makes CRF an alluring 
target for epilepsy treatment. Thus, pharmacological alteration of CRF function might 
normalize pathological activity in circuits mediating stress, such as the HPA axis, without 
producing unwanted side-effects (Hokfelt et al., 2000)(Hokfelt et al. 2000). Indeed, drugs 
that are antagonists at CRF receptors might have a particularly low side-effect burden 
because such compounds would not be expected to disrupt normal physiology in the 
absence of neuropeptide release. CRF-receptor antagonists have been shown to increase 
seizure threshold and are effective in animal models of febrile seizures (Toth et al. 1998). 
This information implies that selective blockers of CRF-receptor activation might be 
useful anticonvulsants for some types of seizures, which with further investigation might 
be useful to treat other epilepsy types. However, CRF system affects a wide range of 
behaviors and physiological processes. Added to these, the complexity of the signaling 
mechanisms makes it much more complicated to successfully target the CRF-system for 
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pharmacotherapy. Most importantly, CRF-mediated TLE animal data requires further 
validation in human tissue to provide us new important information about the role of CRF 
in TLE. Further insights into the complex role of CRF system in the facilitation and 
exacerbation of epilepsy would help us identify new molecular targets for novel AEDs, 
which might help inhibit and/or abrogate the disease pathogenesis.  
 Additionally, CRF-mediated facilitation of IRhR current in the EC might be an 
important mechanism underlying the generation of high-frequency activity in the 
hyperexcitable EC and could become an alternative target for defining antiepileptic 
treatment strategies. In summary, we report that CRF has profound excitatory effects on 
neuronal excitability in the layer II stellate neurons leading to increases in IRhR current and 
thus facilitating the epileptiform activity. A potential mechanism for this enhanced 
excitatory effect could be the increase in the IRhR current. Since the EC is involved in the 
initiation and maintenance of seizures, this study provides a rationale for selective 
targeting of the CRFR2R receptors, through receptor antagonist as a new treatment strategy 
for the TLE 
Future Directions 
 Since drug delivery systems for therapy cannot target individual brain regions and 
cross talk between various peptide and neurotransmitter systems makes it much more 
difficult for single target drug therapies (Arzt and Holsboer, 2006), a deeper 
understanding of signal transduction pathways mediated by CRF system is quintessential 
for specific targeting to obtain greatest therapeutic benefits. Focusing on the downstream 
effects of CRF would help unravel the critical mechanisms underlying the facilitation of 
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CRF-meditated epilepsy not only in the EC, but other brain regions as well. Further 
experimentation with intracellular recordings is required to identify other kind of ligand-
voltage gated ion channels involved in the CRF-mediated, cAMP/PKA-dependent 
modulation of epileptiform activity and increases in neuronal excitability. 
 1TSince our results show that CRF causes membrane depolarization, which could be due 
to the activation of 1T17T cationic conductance or inhibiting background K P
+ 
Pchannels or both, 
leading to neuronal excitability. Firstly, if CRF-induced depolarization is due to the 
activation of cationic conductance, influx of extracellular NaP
+
P should be the major ions 
responsible for the membrane depolarization. This will be tested by replacement of 
extracellular NaCl with the same concentration of NMDG-Cl. Then test whether Ca P
2+
P is 
involved, by substituting extracellular Ca P
2+
P with the same concentration of MgP
2+
P and 
including 1 mM EGTA to chelate the ambient Ca P
2+
P. Blockade of CRF-induced inward 
HC due to the above challenges suggests the role of specific cationic channel. If 
17Tbackground KP
+ 
Pchannels are involved, CRF induced currents should have a reversal 
potential close to the K P
+
P reversal potential. We will measure the reverse potential using a 
ramp protocol (from −120 mV to 0 mV) to construct the voltage–current curve before and 
during the application of CRF (0.1 μM).Under these conditions, if CRF induces a current 
with a reversal potential close to that of theoretical K P
+
P reversal potential calculated by the 
Nernst equation, it suggests that CRF produces membrane depolarization by inhibiting 
background KP
+ 
Pconductance. Using the classic 1TKP
+ 
Pchannel 1T blockers tetraethylammonium 
(TEA), 4-aminopyridine (4-AP) or Cesium (Cs+), the properties of 1TKP
+ 
Pchannels 1T involved 
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Figure 35.  Summary and Future Directions 
 
CRF has been shown to have diverse effects on synaptic transmission, resulting in 
neuronal excitability and epileptogenesis (Hollrigel et al., 1998). Using whole-cell 
recording techniques, the actions of CRF on synaptic transmission would be identified. 
To investigate the actions of CRF on glutamate-mediated synaptic transmission in the 
EC, spontaneous –miniature and evoked-monosyaptic  excitatory post synaptic currents 
would be recorded from the layer-II stellate neurons.  To investigate the actions of CRF 
on GABA-mediated synaptic transmission, spontaneous inhibitory post synaptic currents 
















 Since our results show that CRF enhances IRhR, using surface-protein biotinylation 
method, we will identify whether HCN channels are upregulated in the EC. EC shows 
HCN1 and HCN2 type predominantly. Using specific antibodies for these channels, we 
will identify whether there is CRF is involved in modulation of HCN surface channel 
expression in the EC. 
Limitations of the study: 
 The in vitro model of epilepsy used in the current study have several advantages 
such as, ease of application of various concentrations of drugs, relatively intact local 
circuits of the tissue to visualize and obtain stable intracellular recordings from the layer-
II stellate neurons without any anesthetics or immobilizing agents. These features helped 
to draw important conclusions regarding the role and relevance of CRF and its receptors 
as well as elucidate some of the molecular mechanisms involved in facilitation of 
epileptiform activity in the EC. However, the study has certain limitations when 
extrapolating the results. One of the major limitations is that the in vitro slice 
preparations lack intact functioning circuits of a normal brain, and are thus isolated from 
influences of other hormones, neurotransmitters or neuropeptides. Thus the results may 
differ from intact organism and need to be replicated in vivo, e.g., using CRFR transgenic 
mice to further elucidate the mechanisms underlying CRF-mediated facilitation of 
epilepsy in the EC, with further confirmation by human studies. Despite the major 
limitations, the in vitro slice models of epilepsy have been proven to be very useful as 
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